Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NEWS -- Plus Therapeutics to Provide Update on ReSPECT™ Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
Recurrent glioblastoma and leptomeningeal metastases data have been selected for oral presentations
Pediatric brain cancer plans will be shared via poster session
AUSTIN, Texas, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it will present data from two ongoing clinical trials evaluating the Company’s lead investigational targeted radiotherapeutic, rhenium (186Re) obisbemeda, in recurrent glioblastoma, leptomeningeal metastases, as well as clinical trial plans for pediatric brain cancer at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO) being held November 16-20, 2022 at the Tampa Convention Center in Tampa Bay, Florida.
Accepted abstracts will be published and made available on November 11, 2022 at https://academic.oup.com/neuro-oncology/supplements.
Copies of the presentations will also be available under the Presentations tab of the Investors section of the Company’s website at the time of the presentations at https://ir.plustherapeutics.com.
About Plus Therapeutics
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the development, manufacture, and commercialization of complex and innovative treatments for patients battling cancer and other life-threatening diseases. Our proprietary nanotechnology platform is currently centered around the enhanced delivery of a variety of drugs using novel liposomal encapsulation technology. Liposomal encapsulation has been extensively explored and undergone significant technical and commercial advances since it was first developed. Our platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at https://PlusTherapeutics.com and https://ReSPECT-Trials.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “designed to,” “will,” “can,” “potential,” “focus,” “preparing,” “next steps,” “possibly,” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of 186Re including the ability of 186Re to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company’s future performance including the next steps in developing the Company’s current assets; the Company’s clinical trials including statements regarding the timing and characteristics of the ReSPECT-GBM and ReSPECT-LM clinical trials; possible negative effects of 186Re; the continued evaluation of 186Re including through evaluations in additional patient cohorts; and the intended functions of the Company’s platform and expected benefits from such functions.
The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the Company’s actual results may differ, including materially, from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, the following: the early stage of the Company’s product candidates and therapies, the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash, the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field, among others; and additional risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor Contact
Peter Vozzo
ICR Westwicke
(443) 377-4767
mailto://Peter.Vozzo@westwicke.com
Media Contact
Terri Clevenger
ICR Westwicke
(203) 856-4326
mailto://Terri.Clevenger@westwicke.com
NEWS -- Tokens.com Provides Operational and Capital Update
TORONTO, November 01, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN)(Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), a publicly-traded company that invests in web3 assets and builds businesses linked to crypto staking, the metaverse and play-to-earn gaming, is pleased to share an update on its operational business segments.
Staking operations occur within Tokens.com. Metaverse operations occur within a subsidiary called Metaverse Group. Crypto gaming operations occur within a subsidiary called Hulk Labs. All three businesses are tied together by the utilization of blockchain technology and are linked to high-growth macro trends within web3. Through the sharing of resources and infrastructure across these business segments, Tokens.com is able to efficiently incubate these businesses from inception to revenue generation.
"Since the inception of Tokens.com in 2020, we have built three successful and growing business segments that are all revenue positive and self-sustaining," said Andrew Kiguel, CEO of Tokens.com. "The Company is well capitalized and provides investors with diversified exposure to web3 assets and businesses."
Staking Highlights
Tokens.com currently owns the following tokens used in its staking operations: Ethereum, Solana, Oasis, Polkadot, NFTX, Mana, Ankr and Shiba Inu. Staking is the environmentally friendly equivalent of crypto mining. Stakers use token ownership to validate blocks on the blockchain andare compensated in the form of additional tokens. The tokens owned by the Company are in liquid markets. and from time to time may be liquidated for corporate overhead or rebalancing purposes.
"Staking represents our original business line. The staking process enables our shareholders to earn revenue through the ownership of some of the largest and most liquid crypto assets in the world, which are linked to web3 applications," added Andrew Kiguel, CEO, Tokens.com.
Staking operations are wholly owned and operate within the parent company, Tokens.com. The Company’s token balance grows organically daily via the staking process which compensates the Company with payment in additional tokens. This occurs on a daily basis, all year round. A list of the key tokens owned by the Company is below. Tokens.com owns more aggregate tokens by volume than it ever has before in its history. However, Management notes, the values of these tokens have been and expect to remain volatile. The tokens are selected based on their utility in building web3 infrastructure and potential for appreciation over time.
Tokens.com marks-to-market the value of its tokens at the end of each reporting period. As a result, its quarterly and annual financial statements are subject to these non-cash impacts depending on if the value of the tokens has increased or decreased.
The current market value of the tokens held by the Company is approximately CAD$11.3 million, at current exchange rates and the listed market value of the tokens.
Metaverse Group Highlights
Tokens.com is the majority owner of Metaverse Group, with approximately 58% ownership. Metaverse Group is a web3 technology company with products and services that bring businesses to life in web3 environments, including metaverses, NFTs and the next iteration of retail, ecomm3. It integrates web3 technology solutions with a web3 marketing agency and virtual real estate development services, so that its clients can own ecomm3, engage new audiences, and be first movers.
Currently, Metaverse Group operates 850+ virtual land parcels across 12 metaverses. Of these parcels, it has the most occupancy in the Decentraland metaverse, which is one of the most active web3 metaverses that are currently live. Within Decentraland, Metaverse Group has 179 parcels occupied by tenants. The subsidiary is also in numerous discussions with other potential clients for additional services, such as the creation of NFT loyalty programs, virtual stores, NFT membership programs, and the planning of metaverse-based events.
Currently, Metaverse Group has approximately 85 clients and 8 employees. Metaverse Group continues to see growing demand for its services and has a pipeline of potential clients. Metaverse Group is also building its service offerings with new Augmented Reality and Virtual Reality capabilities. The team and scale of the business are growing at a fast pace.
"We have seen incredible traction with tier one clients at Metaverse Group who choose our team due to our ability to deliver category-leading experiences that leverage our land portfolio and technology," said Lorne Sugarman, CEO of Metaverse Group. "As we scale, we are developing new proprietary technology and leveraging the world’s best immersive digital solutions so that we can continue to be world leaders."
Tokens.com’s management believes that Metaverse Group’s valuation extends beyond its digital land assets, which were last valued in Tokens.com’s quarterly financial statements ending June 30, 2022, at approximately CAD$9.4 million, at current exchange rates. Metaverse Group has successfully leveraged its digital assets through a strong team dedicated to digital land developments, leasing capabilities, and revenue generation.
Hulk Labs Highlights
Tokens.com is the majority owner of Hulk Labs with approximately 94% ownership. Hulk Labs ("Hulk") is a web3 technology company focused on building tools and systems to generate income from Play-to-Earn (P2E) blockchain games. Hulk Labs builds calculators to evaluate the profit potential and longevity of P2E games. In addition, the company is building a global player network to play games on behalf of asset-holders and is building tools to securely delegate and track in-game NFTs.
Hulk has a team of 6 people overseeing its operations. Since its launch in early 2022, the Hulk team has grown to manage over 1,000 player wallets and has a waitlist of over 2,000 players, primarily in African markets including South Africa, Tanzania, and the Democratic Republic of Congo (DRC). The team has a target of surpassing 10,000 players in its network by the end of 2023. This growing player network is a key strategic advantage for Hulk Labs in generating revenue and is in high demand by P2E game developers seeking additional users and liquidity for their titles.
In addition, in 2023, Hulk Labs plans to begin beta testing proprietary software that will connect its player network to interested investors, similar to how companies such as Uber Technologies Inc. connect passengers to drivers. Hulk’s player network will significantly benefit from the proprietary software under development within Playte, Hulk’s acquisition completed July 2022.
Hulk’s players have spent the majority of their time on two P2E titles, Crabada and Thetan Arena. These titles have enabled our team to generate double digit (10%+) gross monthly returns on our asset base.
Hulk has currently deployed approximately CAD$540k across several P2E and NFT projects. Many of these investments are in projects such as CryptoPunks and NFTX which provide utility to the broader NFT ecosystem.
"The rapid development of the P2E industry and the revenue and traction Hulk Labs has been able to gain since our launch less than a year ago has us on track to win significant market share in the P2E space," commented Deven Soni, President of Hulk Labs.
In August 2022, Hulk Labs raised approximately CAD$680k of strategic capital at current exchange rates. That transaction was completed at a CAD$10.9 million pre-money valuation which equates to a post-money valuation for Hulk Labs of approximately CAD$11.6 million, at current exchange rates. Since August, the subsidiary has achieved many new milestones and is now revenue positive.
Domain Names
Tokens.com also owns several domain names it believes to have market value. This not only includes the Tokens.com domain, but also tokenstrading.com and tokensart.com. Metaverse Group owns metaversegroup.com. While the value of domain names is not easy to pinpoint and can vary in different sectors and markets, management feels these domains do have a market value, particularly in the crypto and metaverse sectors. Management has received inquiries regarding our desire to sell the Tokens.com domain name, with soft offers in the mid-seven figure range. At this time, Management feels retaining the domain name is its best use, however, reserves the option to reevaluate that decision under different circumstances.
Capitalization
As at the end of the last quarter, Tokens.com and its subsidiaries held CAD$7.8 million in cash, at current exchange rates. In addition, the Company is able to liquidate its digital assets used in the staking operations within a short period of time for additional capital if required. Management at Tokens.com does not believe the current market price for its common shares reflects the inherent value in the Company or the aggregate value of its businesses, digital assets, and cash. As such, on October 27th, Tokens.com announced the launch of a normal course issuer bid program to buy back its shares in the market for cancellation. Tokens.com has 96,926,757 shares issued and outstanding and a public float of 72,377,444.
Tokens.com does not foresee a requirement to raise capital in the near term given its three business segments are revenue positive, its low operating overhead, and its existing cash and token balances.
Our most recent quarterly financial statements, ending June 30th, 2022 and reviewed by the Company’s auditors, had total assets of approximately CAD$31.0 million including a cash balance of approximately CAD$7.8 million, at current exchange rates. This equates to CAD$0.32 per common share in asset values.
Tokens.com’s cash at the last reported quarter ending June 30th, 2022, and its current value of tokens is equal to approximately CAD$19.1 million, or CAD$0.20 per common share at current exchange rates. This value does not include the additional value of the businesses and digital assets contained within Hulk Labs and Metaverse Group described above.
Tokens.com expects to release its audited year-end financial statements for the nine months ended September 30th, in mid-December.
About Tokens.com
Tokens.com Corp is a publicly traded company that invests in web3 assets and builds web3 businesses. The Company focuses on three operating segments: i) crypto staking, ii) the metaverse and, iii) play-to-earn crypto gaming. Tokens.com owns digital assets and operating businesses within each of these three segments.
Staking operations occur within Tokens.com. Metaverse operations occur within a subsidiary called Metaverse Group. Crypto gaming operations occur within a subsidiary called Hulk Labs. All three businesses are tied together by the utilization of blockchain technology and are linked to high-growth macro trends within web3. Through the sharing resources and infrastructure across these business segments, Tokens.com is able to efficiently incubate these businesses from inception to revenue generation.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities on Twitter, LinkedIn, and YouTube.
About Hulk Labs
Hulk Labs is a web3 technology company focused on building tools and systems to generate income from Play-to-Earn (P2E) blockchain games. Hulk Labs builds calculators to evaluate the profit potential and longevity of P2E games. In addition, the company is building a global player network to play games on behalf of asset-holders and is building tools to securely delegate and track in-game NFTs. Hulk Labs is a subsidiary of Tokens.com, a publicly- traded company that invests in web3 assets and businesses.
For further information please visit https://hulklabs.com.
About Metaverse Group
Metaverse Group is a web3 technology company with products and services that bring businesses to life in web3 environments, including metaverses, NFTs and the next iteration of retail, ecomm3. We integrate web3 technology solutions with a web3 marketing agency and virtual real estate development services, so that our clients can own ecomm3, engage new audiences, and be first movers. The company also holds an eight-figure metaverse real estate portfolio spanning over 10+ metaverses.
Our ownership over 750 parcels of virtual land and relationships with different metaverses and industry players allow us to deliver category leading solutions that have been recognized by CNBC, Forbes, the Economist and the Wall Street Journal. Tokens.com, a publicly- traded company, is the majority owner of Metaverse Group.
For further information please visit https://metaversegroup.com.
Forward-looking Statements
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at https://www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221101005831/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media Contact: Ali Clarke – Talk Shop Media
Email: mailto://ali@talkshopmedia.com
NEWS -- Tokens.com Provides Operational and Capital Update
TORONTO, November 01, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN)(Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), a publicly-traded company that invests in web3 assets and builds businesses linked to crypto staking, the metaverse and play-to-earn gaming, is pleased to share an update on its operational business segments.
Staking operations occur within Tokens.com. Metaverse operations occur within a subsidiary called Metaverse Group. Crypto gaming operations occur within a subsidiary called Hulk Labs. All three businesses are tied together by the utilization of blockchain technology and are linked to high-growth macro trends within web3. Through the sharing of resources and infrastructure across these business segments, Tokens.com is able to efficiently incubate these businesses from inception to revenue generation.
"Since the inception of Tokens.com in 2020, we have built three successful and growing business segments that are all revenue positive and self-sustaining," said Andrew Kiguel, CEO of Tokens.com. "The Company is well capitalized and provides investors with diversified exposure to web3 assets and businesses."
Staking Highlights
Tokens.com currently owns the following tokens used in its staking operations: Ethereum, Solana, Oasis, Polkadot, NFTX, Mana, Ankr and Shiba Inu. Staking is the environmentally friendly equivalent of crypto mining. Stakers use token ownership to validate blocks on the blockchain andare compensated in the form of additional tokens. The tokens owned by the Company are in liquid markets. and from time to time may be liquidated for corporate overhead or rebalancing purposes.
"Staking represents our original business line. The staking process enables our shareholders to earn revenue through the ownership of some of the largest and most liquid crypto assets in the world, which are linked to web3 applications," added Andrew Kiguel, CEO, Tokens.com.
Staking operations are wholly owned and operate within the parent company, Tokens.com. The Company’s token balance grows organically daily via the staking process which compensates the Company with payment in additional tokens. This occurs on a daily basis, all year round. A list of the key tokens owned by the Company is below. Tokens.com owns more aggregate tokens by volume than it ever has before in its history. However, Management notes, the values of these tokens have been and expect to remain volatile. The tokens are selected based on their utility in building web3 infrastructure and potential for appreciation over time.
Tokens.com marks-to-market the value of its tokens at the end of each reporting period. As a result, its quarterly and annual financial statements are subject to these non-cash impacts depending on if the value of the tokens has increased or decreased.
The current market value of the tokens held by the Company is approximately CAD$11.3 million, at current exchange rates and the listed market value of the tokens.
Metaverse Group Highlights
Tokens.com is the majority owner of Metaverse Group, with approximately 58% ownership. Metaverse Group is a web3 technology company with products and services that bring businesses to life in web3 environments, including metaverses, NFTs and the next iteration of retail, ecomm3. It integrates web3 technology solutions with a web3 marketing agency and virtual real estate development services, so that its clients can own ecomm3, engage new audiences, and be first movers.
Currently, Metaverse Group operates 850+ virtual land parcels across 12 metaverses. Of these parcels, it has the most occupancy in the Decentraland metaverse, which is one of the most active web3 metaverses that are currently live. Within Decentraland, Metaverse Group has 179 parcels occupied by tenants. The subsidiary is also in numerous discussions with other potential clients for additional services, such as the creation of NFT loyalty programs, virtual stores, NFT membership programs, and the planning of metaverse-based events.
Currently, Metaverse Group has approximately 85 clients and 8 employees. Metaverse Group continues to see growing demand for its services and has a pipeline of potential clients. Metaverse Group is also building its service offerings with new Augmented Reality and Virtual Reality capabilities. The team and scale of the business are growing at a fast pace.
"We have seen incredible traction with tier one clients at Metaverse Group who choose our team due to our ability to deliver category-leading experiences that leverage our land portfolio and technology," said Lorne Sugarman, CEO of Metaverse Group. "As we scale, we are developing new proprietary technology and leveraging the world’s best immersive digital solutions so that we can continue to be world leaders."
Tokens.com’s management believes that Metaverse Group’s valuation extends beyond its digital land assets, which were last valued in Tokens.com’s quarterly financial statements ending June 30, 2022, at approximately CAD$9.4 million, at current exchange rates. Metaverse Group has successfully leveraged its digital assets through a strong team dedicated to digital land developments, leasing capabilities, and revenue generation.
Hulk Labs Highlights
Tokens.com is the majority owner of Hulk Labs with approximately 94% ownership. Hulk Labs ("Hulk") is a web3 technology company focused on building tools and systems to generate income from Play-to-Earn (P2E) blockchain games. Hulk Labs builds calculators to evaluate the profit potential and longevity of P2E games. In addition, the company is building a global player network to play games on behalf of asset-holders and is building tools to securely delegate and track in-game NFTs.
Hulk has a team of 6 people overseeing its operations. Since its launch in early 2022, the Hulk team has grown to manage over 1,000 player wallets and has a waitlist of over 2,000 players, primarily in African markets including South Africa, Tanzania, and the Democratic Republic of Congo (DRC). The team has a target of surpassing 10,000 players in its network by the end of 2023. This growing player network is a key strategic advantage for Hulk Labs in generating revenue and is in high demand by P2E game developers seeking additional users and liquidity for their titles.
In addition, in 2023, Hulk Labs plans to begin beta testing proprietary software that will connect its player network to interested investors, similar to how companies such as Uber Technologies Inc. connect passengers to drivers. Hulk’s player network will significantly benefit from the proprietary software under development within Playte, Hulk’s acquisition completed July 2022.
Hulk’s players have spent the majority of their time on two P2E titles, Crabada and Thetan Arena. These titles have enabled our team to generate double digit (10%+) gross monthly returns on our asset base.
Hulk has currently deployed approximately CAD$540k across several P2E and NFT projects. Many of these investments are in projects such as CryptoPunks and NFTX which provide utility to the broader NFT ecosystem.
"The rapid development of the P2E industry and the revenue and traction Hulk Labs has been able to gain since our launch less than a year ago has us on track to win significant market share in the P2E space," commented Deven Soni, President of Hulk Labs.
In August 2022, Hulk Labs raised approximately CAD$680k of strategic capital at current exchange rates. That transaction was completed at a CAD$10.9 million pre-money valuation which equates to a post-money valuation for Hulk Labs of approximately CAD$11.6 million, at current exchange rates. Since August, the subsidiary has achieved many new milestones and is now revenue positive.
Domain Names
Tokens.com also owns several domain names it believes to have market value. This not only includes the Tokens.com domain, but also tokenstrading.com and tokensart.com. Metaverse Group owns metaversegroup.com. While the value of domain names is not easy to pinpoint and can vary in different sectors and markets, management feels these domains do have a market value, particularly in the crypto and metaverse sectors. Management has received inquiries regarding our desire to sell the Tokens.com domain name, with soft offers in the mid-seven figure range. At this time, Management feels retaining the domain name is its best use, however, reserves the option to reevaluate that decision under different circumstances.
Capitalization
As at the end of the last quarter, Tokens.com and its subsidiaries held CAD$7.8 million in cash, at current exchange rates. In addition, the Company is able to liquidate its digital assets used in the staking operations within a short period of time for additional capital if required. Management at Tokens.com does not believe the current market price for its common shares reflects the inherent value in the Company or the aggregate value of its businesses, digital assets, and cash. As such, on October 27th, Tokens.com announced the launch of a normal course issuer bid program to buy back its shares in the market for cancellation. Tokens.com has 96,926,757 shares issued and outstanding and a public float of 72,377,444.
Tokens.com does not foresee a requirement to raise capital in the near term given its three business segments are revenue positive, its low operating overhead, and its existing cash and token balances.
Our most recent quarterly financial statements, ending June 30th, 2022 and reviewed by the Company’s auditors, had total assets of approximately CAD$31.0 million including a cash balance of approximately CAD$7.8 million, at current exchange rates. This equates to CAD$0.32 per common share in asset values.
Tokens.com’s cash at the last reported quarter ending June 30th, 2022, and its current value of tokens is equal to approximately CAD$19.1 million, or CAD$0.20 per common share at current exchange rates. This value does not include the additional value of the businesses and digital assets contained within Hulk Labs and Metaverse Group described above.
Tokens.com expects to release its audited year-end financial statements for the nine months ended September 30th, in mid-December.
About Tokens.com
Tokens.com Corp is a publicly traded company that invests in web3 assets and builds web3 businesses. The Company focuses on three operating segments: i) crypto staking, ii) the metaverse and, iii) play-to-earn crypto gaming. Tokens.com owns digital assets and operating businesses within each of these three segments.
Staking operations occur within Tokens.com. Metaverse operations occur within a subsidiary called Metaverse Group. Crypto gaming operations occur within a subsidiary called Hulk Labs. All three businesses are tied together by the utilization of blockchain technology and are linked to high-growth macro trends within web3. Through the sharing resources and infrastructure across these business segments, Tokens.com is able to efficiently incubate these businesses from inception to revenue generation.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities on Twitter, LinkedIn, and YouTube.
About Hulk Labs
Hulk Labs is a web3 technology company focused on building tools and systems to generate income from Play-to-Earn (P2E) blockchain games. Hulk Labs builds calculators to evaluate the profit potential and longevity of P2E games. In addition, the company is building a global player network to play games on behalf of asset-holders and is building tools to securely delegate and track in-game NFTs. Hulk Labs is a subsidiary of Tokens.com, a publicly- traded company that invests in web3 assets and businesses.
For further information please visit https://hulklabs.com.
About Metaverse Group
Metaverse Group is a web3 technology company with products and services that bring businesses to life in web3 environments, including metaverses, NFTs and the next iteration of retail, ecomm3. We integrate web3 technology solutions with a web3 marketing agency and virtual real estate development services, so that our clients can own ecomm3, engage new audiences, and be first movers. The company also holds an eight-figure metaverse real estate portfolio spanning over 10+ metaverses.
Our ownership over 750 parcels of virtual land and relationships with different metaverses and industry players allow us to deliver category leading solutions that have been recognized by CNBC, Forbes, the Economist and the Wall Street Journal. Tokens.com, a publicly- traded company, is the majority owner of Metaverse Group.
For further information please visit https://metaversegroup.com.
Forward-looking Statements
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at https://www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221101005831/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media Contact: Ali Clarke – Talk Shop Media
Email: mailto://ali@talkshopmedia.com
I see no tons of selling maybe a new eyeglass prescription is due.
NEWS -- National Institutes of Health Grants Phase I SBIR Award to CytoSorbents to Test Novel Polymers for Cytokine and Endotoxin Removal from Septic Porcine Plasma
Goal is to advance new combined blood purification technologies to treat Gram negative sepsis – a deadly global killer
PRINCETON, N.J., Oct. 31, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced today that the National Institute of General Medical Sciences (NIGMS), a division of the U.S. National Institutes of Health, has granted CytoSorbents a Phase I Small Business Innovation Research (SBIR) award valued at $281,835. The eight-month award (Award #1R43GM144973-01) will allow CytoSorbents to test the ability of its novel and existing polymers to remove cytokines and lipopolysaccharide (LPS) endotoxin from septic porcine plasma. LPS endotoxin, released by Gram-negative bacteria such as E. coli, Salmonella, Pseudomonas, Klebsiella, and Legionella, is a well-known potent and deadly trigger of sepsis and septic shock by activating the immune system and generating a cytokine storm that can lead to massive, uncontrolled systemic inflammation, organ failure, and potentially death.
Goal is to advance new combined blood purification technologies to treat Gram negative sepsis - a deadly global killer
Dr. Phillip Chan, MD, PhD, Chief Executive Officer of CytoSorbents stated, "Gram-negative infections play an important and feared role in sepsis, accounting for approximately 40% of cases of septic shock, and more than 30% of hospital-acquired infections. These patients tend to be very sick and have a high risk of death. We are the pioneer in the treatment of sepsis and septic shock by targeting cytokine storm and deadly inflammation with our European Union approved extracorporeal cytokine adsorber, CytoSorb®. But we believe the combination of extracorporeal cytokine and endotoxin removal from blood, in conjunction with antibiotics, may be an even more effective therapy for Gram-negative infections, and will help us to save more lives. We are grateful for the support from NIGMS to conduct the preliminary in vitro work needed before we evaluate our new polymers in a pig model of Gram-negative sepsis in the future."
Sepsis is the overzealous immune response to an infection and is responsible for approximately one in every five deaths worldwide each year. This has led the World Health Organization (WHO) to declare it a "global health priority." Sepsis accounts for approximately 10-20% of all intensive care unit (ICU) admissions, where patients either have sepsis when admitted to the ICU, or develop sepsis as a result of a nosocomial or hospital-acquired infection while in the ICU. Gram-negative infections commonly trigger septic shock, a serious complication of sepsis where the blood pressure drops to dangerously low levels and organ failure and death can ensue. Despite antibiotics and the best standard of care, septic shock still has a mortality of 35-50%.
The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and in cardiac surgery through blood purification. Its lead product, CytoSorb®, is approved in the European Union and distributed in 75 countries worldwide. It is an extracorporeal cytokine adsorber that reduces "cytokine storm" or "cytokine release syndrome" in common critical illnesses that can lead to massive inflammation, organ failure and patient death. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments. CytoSorb is also used during and after cardiothoracic surgery to remove inflammatory mediators that can lead to postoperative complications, including multiple organ failure. As of June 30, 2022, more than 179,000 CytoSorb devices have been used cumulatively. CytoSorb was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor and rivaroxaban removal in cardiothoracic surgery procedures. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure. The DrugSorb™-ATR antithrombotic removal system, based on the same polymer technology as CytoSorb, also received two FDA Breakthrough Device Designations, one for the removal of ticagrelor and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic procedures. The company has initiated two FDA-approved pivotal studies to support FDA marketing approval of DrugSorb-ATR in the United States. The first is the randomized, controlled STAR-T (Safe and Timely Antithrombotic Removal-Ticagrelor) study of 120 patients at 30 centers to evaluate whether intraoperative use of DrugSorb-ATR can reduce the perioperative risk of bleeding in patients receiving ticagrelor and undergoing cardiothoracic surgery. The second study is the STAR-D (Safe and Timely Antithrombotic Removal-Direct Oral Anticoagulants) randomized, controlled trial of 120 patients at 30 centers evaluating the intraoperative use of DrugSorb-ATR to reduce perioperative bleeding risk in patients undergoing cardiothoracic surgery and taking direct oral anticoagulants, including apixaban and rivaroxaban.
CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of more than $48 million from DARPA, the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S. Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM), Air Force Material Command (USAF/AFMC), and others. The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, DrugSorb™-ATR, ContrastSorb, and others. For more information, please visit the Company's websites at https://www.cytosorbents.com and https://www.cytosorb.com or follow us on Facebook and Twitter.
Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, expectations regarding the future impacts of COVID-19 or the ongoing conflict between Russia and the Ukraine, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 10, 2022, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
Please Click to Follow Us on Facebook and Twitter
Company Contact:
Kathleen Bloch
(732) 398-5429
mailto://kbloch@cytosorbents.com
U.S. Public Relations Contact:
Eric Kim
Rubenstein Public Relations
212-805-3052
mailto://ekim@rubensteinpr.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/national-institutes-of-health-grants-phase-i-sbir-award-to-cytosorbents-to-test-novel-polymers-for-cytokine-and-endotoxin-removal-from-septic-porcine-plasma-301663126.html
SOURCE CytoSorbents Corporation
NEWS -- Lineage Cell Therapeutics Appoints Jill Howe as Chief Financial Officer
CARLSBAD, Calif., October 31, 2022--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that Jill Howe will join as the Company’s Chief Financial Officer, effective November 14, 2022. Ms. Howe brings more than 20 years of significant strategic, financial, and operational experience to Lineage, with an emphasis on capital strategy, corporate finance, treasury management, global infrastructure, and operational excellence. Ms. Howe has successfully built biotechnology organizations and implemented operational infrastructures alongside the execution of over $1.66 billion of capital raising transactions and will bring extensive strategic experience to the role. Most recently, Ms. Howe was Chief Financial Officer of DTx Pharma, and prior to that, was Vice President of Finance and Treasurer at Gossamer Bio, Inc., serving an integral role in the company’s initial public offering (IPO) and concurrent listing on the Nasdaq Global Select Market, various follow-on and debt deals, and overseeing all aspects of finance and accounting operations globally.
"Jill is a wonderful addition to our executive team as we work to establish Lineage as a leader in cell therapy and cell transplant medicine," stated Brian M. Culley, Lineage CEO. "She is a successful executive with an extensive track record of execution in capital raising, strategic financial management, global expansion, and support, as well as mergers & acquisitions, and reflects the newest expansion of our team. Our continued growth will allow Lineage to exhibit greater productivity and increase the breadth of what we are able to accomplish in the months and years ahead."
Ms. Howe most recently served as Chief Financial Officer of DTx Pharma, a biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease. From 2018 to 2021, she served as Vice President of Finance and Treasurer for Gossamer Bio, Inc. (NASDAQ: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, where she managed all aspects of finance operations, accounting, and global IT and real estate efforts, including the building-out of world-class labs and office space. She also served as a Board member of all Irish and Luxembourg subsidiaries of Gossamer Bio. From 2016 through 2017 she served as Controller & Director of Finance at Amplyx Pharmaceuticals, Inc., a company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems, which was subsequently acquired by Pfizer, Inc. From 2013 to 2016 she served as Controller & Director of Finance at Receptos, Inc. (NASDAQ: RCPT), which was subsequently acquired by Celgene, Inc. for more than $7 billion. Prior to that, from 2006 to 2013 she worked in various accounting roles, leading up to Director of Finance, at Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), which was acquired by Pernix in 2012. Ms. Howe earned her Bachelor of Arts in Accounting from San Diego State University and serves on the Board of Directors of various nonprofit, private and public biotechnology companies. In 2022, Ms. Howe won the 2022 CFO of the Year Award in the small business category from the San Diego Business Journal and was specifically recognized for her leadership in building and managing successful financial teams, laying the groundwork for success, and as a San Diegan, for contributions to the community through her local charity work.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include five allogeneic ("off-the-shelf") product candidates: (i) OpRegen, a retinal pigment epithelial cell therapy in development for the treatment of geographic atrophy secondary to age-related macular degeneration, is being developed under a worldwide collaboration with Roche and Genentech, a member of the Roche Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; (iii) VAC2, a dendritic cell therapy produced from Lineage’s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer; (iv) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; and (v) PNC1, a photoreceptor neural cell therapy for the treatment of vision loss due to photoreceptor dysfunction or damage. For more information, please visit https://www.lineagecell.com or follow the company on Twitter @LineageCell.
Forward-Looking Statements
Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as "believe," "aim," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "can," "plan," "potential," "predict," "seek," "should," "would," "contemplate," "project," "target," "tend to," or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to: Ms. Howe’s employment with Lineage and the anticipated or implied benefits thereof to Lineage and Lineage’s continued growth and ability to exhibit greater productivity in the future. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, but not limited to, the risks and uncertainties inherent in Lineage’s business and other risks discussed in Lineage’s filings with the Securities and Exchange Commission (SEC). Lineage’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading "Risk Factors" in Lineage’s periodic reports with the SEC, including Lineage’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the SEC and its other reports, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221031005220/en/
Contacts
Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
(mailto://ir@lineagecell.com)
(442) 287-8963
LifeSci Advisors
Daniel Ferry
(mailto://daniel@lifesciadvisors.com)
(617) 430-7576
Russo Partners – Media Relations
Nic Johnson or David Schull
(mailto://Nic.johnson@russopartnersllc.com)
(mailto://David.schull@russopartnersllc.com)
(212) 845-4242
NEWS -- Tokens.com Announces Normal Course Issuer Bid Program
TORONTO, October 27, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN)(Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), a publicly-traded company that invests in web3 assets and builds businesses linked to crypto staking, the metaverse and play-to-earn gaming, is pleased to announce the NEO Exchange ("NEO") has accepted its notice to implement a normal course issuer bid ("NCIB") to purchase, for cancellation, up to 3,000,000 of its common shares ("Shares"), or approximately 4.1 percent of the Company's public float, as at October 26, 2022.
Tokens.com’s Board of Directors believes that the market price of the Company's Shares, from time to time, may not reflect the inherent value of the Company and purchases of Shares pursuant to the NCIB may represent an appropriate and desirable use of funds.
"Our shares have been impacted by depressed crypto prices, and macro economic events and headlines, that are not linked to the performance of our businesses. Although our three business segments have positive revenue growth, this has not materialized into market recognition of the value within the Company," said Andrew Kiguel, CEO of Tokens.com. "Tokens.com remains viable, well capitalized, and committed to growing its web3 businesses. Management does not believe that our shares currently reflect the value of the Company."
Purchase of the Shares may commence on November 01, 2022 and will expire on the earlier of October 31, 2023 or the date on which the Company has either acquired the maximum number of Shares allowable or otherwise decides not to make any further repurchases. Purchases of Tokens.com’s Shares under the NCIB may be made through the facilities of the NEO and alternative trading systems by means of open market transactions or by such other means as may be permitted by the Canadian Securities Administrators (the "CSA") and under applicable securities laws, including by private agreement pursuant to issuer bid exemption orders issued by applicable securities regulatory authorities.
The price the Company will pay for any Shares will be the market price at the time of purchase or such other price as may be permitted by the CSA. Any private purchase made under an exemption order issued by a securities regulatory authority will generally be at a discount to the prevailing market price. In connection with the NCIB, Tokens.com will enter into an automatic purchase plan ("Plan") with its designated broker to allow for purchases of its Shares during internal blackout periods. Such purchases would be at the discretion of the broker based on parameters established by the Company prior to any blackout period or any period when it is in possession of material undisclosed information.
Outside of these periods, the Shares will be repurchased in accordance with management's discretion, subject to applicable law. The Plan may be terminated by Tokens.com or its broker in accordance with its terms or will terminate on the expiry of the NCIB. As of October 26, 2022, the Company has 96,926,757 Shares issued and outstanding and a public float of 72,377,444. Tokens.com will not acquire, through the facilities of the NEO and alternative trading systems, more than 56,146 Shares during a trading day (which is equal to 25% of 224,586 Shares, being the average daily trading volume on all exchanges for six calendar months prior to the date hereof), subject to certain exceptions for block purchases. The actual number of Shares that will be repurchased under the NCIB, and the timing of any such purchases, will be determined by Tokens.com on management's discretion, subject to applicable securities laws. There cannot be any assurances as to how many Shares, if any, will ultimately be acquired by the Company.
About Tokens.com
Tokens.com Corp is a publicly traded company that invests in web3 assets and builds web3 businesses. The Company focuses on three operating segments: i) crypto staking, ii) the metaverse and, iii) play-to-earn crypto gaming. Tokens.com owns digital assets and operating businesses within each of these three segments.
Staking operations occur within Tokens.com. Metaverse operations occur within a subsidiary called Metaverse Group. Crypto gaming operations occur within a subsidiary called Hulk Labs. All three businesses are tied together by the utilization of blockchain technology and are linked to high-growth macro trends within web3. Through sharing resources and infrastructure across these business segments, Tokens.com is able to efficiently incubate these businesses from inception to revenue generation.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities on Twitter, LinkedIn, and YouTube.
Forward-looking Statements
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at https://www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221027005618/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media Contact: Ali Clarke – Talk Shop Media
Email: mailto://ali@talkshopmedia.com
NEWS -- Tokens.com Announces Normal Course Issuer Bid Program
TORONTO, October 27, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN)(Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), a publicly-traded company that invests in web3 assets and builds businesses linked to crypto staking, the metaverse and play-to-earn gaming, is pleased to announce the NEO Exchange ("NEO") has accepted its notice to implement a normal course issuer bid ("NCIB") to purchase, for cancellation, up to 3,000,000 of its common shares ("Shares"), or approximately 4.1 percent of the Company's public float, as at October 26, 2022.
Tokens.com’s Board of Directors believes that the market price of the Company's Shares, from time to time, may not reflect the inherent value of the Company and purchases of Shares pursuant to the NCIB may represent an appropriate and desirable use of funds.
"Our shares have been impacted by depressed crypto prices, and macro economic events and headlines, that are not linked to the performance of our businesses. Although our three business segments have positive revenue growth, this has not materialized into market recognition of the value within the Company," said Andrew Kiguel, CEO of Tokens.com. "Tokens.com remains viable, well capitalized, and committed to growing its web3 businesses. Management does not believe that our shares currently reflect the value of the Company."
Purchase of the Shares may commence on November 01, 2022 and will expire on the earlier of October 31, 2023 or the date on which the Company has either acquired the maximum number of Shares allowable or otherwise decides not to make any further repurchases. Purchases of Tokens.com’s Shares under the NCIB may be made through the facilities of the NEO and alternative trading systems by means of open market transactions or by such other means as may be permitted by the Canadian Securities Administrators (the "CSA") and under applicable securities laws, including by private agreement pursuant to issuer bid exemption orders issued by applicable securities regulatory authorities.
The price the Company will pay for any Shares will be the market price at the time of purchase or such other price as may be permitted by the CSA. Any private purchase made under an exemption order issued by a securities regulatory authority will generally be at a discount to the prevailing market price. In connection with the NCIB, Tokens.com will enter into an automatic purchase plan ("Plan") with its designated broker to allow for purchases of its Shares during internal blackout periods. Such purchases would be at the discretion of the broker based on parameters established by the Company prior to any blackout period or any period when it is in possession of material undisclosed information.
Outside of these periods, the Shares will be repurchased in accordance with management's discretion, subject to applicable law. The Plan may be terminated by Tokens.com or its broker in accordance with its terms or will terminate on the expiry of the NCIB. As of October 26, 2022, the Company has 96,926,757 Shares issued and outstanding and a public float of 72,377,444. Tokens.com will not acquire, through the facilities of the NEO and alternative trading systems, more than 56,146 Shares during a trading day (which is equal to 25% of 224,586 Shares, being the average daily trading volume on all exchanges for six calendar months prior to the date hereof), subject to certain exceptions for block purchases. The actual number of Shares that will be repurchased under the NCIB, and the timing of any such purchases, will be determined by Tokens.com on management's discretion, subject to applicable securities laws. There cannot be any assurances as to how many Shares, if any, will ultimately be acquired by the Company.
About Tokens.com
Tokens.com Corp is a publicly traded company that invests in web3 assets and builds web3 businesses. The Company focuses on three operating segments: i) crypto staking, ii) the metaverse and, iii) play-to-earn crypto gaming. Tokens.com owns digital assets and operating businesses within each of these three segments.
Staking operations occur within Tokens.com. Metaverse operations occur within a subsidiary called Metaverse Group. Crypto gaming operations occur within a subsidiary called Hulk Labs. All three businesses are tied together by the utilization of blockchain technology and are linked to high-growth macro trends within web3. Through sharing resources and infrastructure across these business segments, Tokens.com is able to efficiently incubate these businesses from inception to revenue generation.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities on Twitter, LinkedIn, and YouTube.
Forward-looking Statements
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at https://www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221027005618/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media Contact: Ali Clarke – Talk Shop Media
Email: mailto://ali@talkshopmedia.com
NEWS -- Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights
Conference call and webcast to take place on Monday, November 7, 2022, at 8:30 a.m. ET
SAN DIEGO, Calif. and CALGARY, AB, Oct. 27, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Monday, November 7, 2022, at 8:30 a.m. ET to discuss a corporate update and financial results for the third quarter of 2022.
Conference Call & Webcast
Date: Monday, November 7, 2022
Time: 8:30 a.m. ET
Dial In – North American Toll-Free: (888) 664-6383
Dial In – International: (416) 764-8650
Conference ID (if needed): 4240-6541
Webcast: please click here
A webcast of the call will also be available on the Investor Relations page of Oncolytics' website, available by clicking here, and will be archived for three months. A dial in replay will be available for one week and can be accessed by dialing (888) 390-0541 (North America) or (416) 764-8677 (International) and using replay code: 406-541#.
About Oncolytics Biotech Inc.
Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Oncolytics is currently conducting and planning clinical trials evaluating pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies as it advances towards a registration study in metastatic breast cancer. For further information, please visit: https://www.oncolyticsbiotech.com.
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the mode of action and potential and benefits of pelareorep as a cancer therapeutic; Oncolytics' plans to advance towards a registration study in metastatic breast cancer; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. In particular, we may be impacted by business interruptions resulting from COVID-19 coronavirus, including operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labour shortages, travel and shipping disruption, and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how Oncolytics may be affected if the COVID-19 pandemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.
Company Contact
Jon Patton
Director of IR & Communication
+1-858-886-7813
mailto://jpatton@oncolytics.ca
Investor Relations for Oncolytics
Timothy McCarthy
LifeSci Advisors
+1-917-679-9282
mailto://tim@lifesciadvisors.com
NEWS -- Tokens.com subsidiary, Hulk Labs, Integrates over 1000 Players into its Player Network
TORONTO, October 26, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), a publicly-traded company that invests in web3 assets and builds businesses linked to crypto staking, the metaverse and play-to-earn gaming, is pleased to announce its subsidiary, Hulk Labs, has successfully integrated over a thousand player wallets into its network, with a primary focus on Africa.
Hulk Labs has initially allocated over US$100,000 into gaming assets that have been deployed to players in Africa, in markets including Tanzania, South Africa, and via its exclusive contract with the Democratic Republic of Congo ("the DRC"). To date, gaming assets in its top titles (Crabada and Thetan Arena) are returning between 18% and 24% per month in revenue. Hulk Labs has over 3,000 players on the waitlist to join its network across Africa. It is expected that Hulk Labs will continue to add hundreds of players each month and deploy further capital, with a target of getting to 10,000 players by the end of 2023.
Hulk continues to leverage its in-house software tools to scale its ability to manage a growing number of assets and players. In addition, in 2023, Hulk Labs will begin beta testing proprietary software that will connect its player network to interested investors, similar to how Uber connects passengers to drivers.
"Hulk Labs which has grown exponentially since its launch earlier this year and has sights on becoming one of the largest gaming guilds in the world," said Andrew Kiguel, CEO of Tokens.com. "Our partnerships in Africa successfully created new income opportunities leveraging the blockchain. We will continue to forge the business ahead and will be well equipped for when the crypto markets turn."
Hulk Labs is focused on three primary objectives. The first is identifying the best income-generation opportunities across the P2E economy by evaluating hundreds of the top P2E games and creating calculators to evaluate the profit potential and expected longevity of the games. Hulk Labs publishes many of these calculators at hulklabs.com for no cost.
Second, Hulk Labs buys P2E gaming assets (NFTs) that identify with the most profit potential and delegates them to a network of players in its network, located primarily in Africa.
Finally, the Company continues to build tools to streamline the delegation (sharing) and tracking of its P2E assets to various players. Hulk Labs has built tools to securely create and monitor thousands of cryptocurrency wallets, administer assets to these wallets while still maintaining custody of its assets, track player performance during gameplay, and streamline the transfer of tokens required for gameplay. The team is focused on scaling its products to support a wide variety of blockchains and games.
About Tokens.com
Tokens.com Corp is a publicly traded company that invests in web3 assets and builds web3 businesses. The Company focuses on three operating segments: i) crypto staking, ii) the metaverse and, iii) play-to-earn crypto gaming. Tokens.com owns digital assets and operating businesses within each of these three segments.
Staking operations occur within Tokens.com. Metaverse operations occur within a subsidiary called Metaverse Group. Crypto gaming operations occur within a subsidiary called Hulk Labs. All three businesses are tied together by the utilization of blockchain technology and are linked to high-growth macro trends within web3. Through sharing resources and infrastructure across these business segments, Tokens.com is able to efficiently incubate these businesses from inception to revenue generation.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities on Twitter, LinkedIn, and YouTube.
About Hulk Labs
Hulk Labs is a web3 technology company focused on building tools and systems to generate income from Play-to-Earn (P2E) blockchain games. Hulk Labs builds calculators to evaluate the profit potential and longevity of P2E games. In addition, the company is building a global player network to play games on behalf of asset-holders and is building tools to securely delegate and track in-game NFTs. Hulk Labs is a subsidiary of Tokens.com, a publicly- traded company that invests in web3 assets and businesses.
For further information please visit https://hulklabs.com.
Forward-looking Statements
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at https://www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221026005148/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media Contact: Ali Clarke – Talk Shop Media
Email: mailto://ali@talkshopmedia.com
NEWS -- Tokens.com subsidiary, Hulk Labs, Integrates over 1000 Players into its Player Network
TORONTO, October 26, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), a publicly-traded company that invests in web3 assets and builds businesses linked to crypto staking, the metaverse and play-to-earn gaming, is pleased to announce its subsidiary, Hulk Labs, has successfully integrated over a thousand player wallets into its network, with a primary focus on Africa.
Hulk Labs has initially allocated over US$100,000 into gaming assets that have been deployed to players in Africa, in markets including Tanzania, South Africa, and via its exclusive contract with the Democratic Republic of Congo ("the DRC"). To date, gaming assets in its top titles (Crabada and Thetan Arena) are returning between 18% and 24% per month in revenue. Hulk Labs has over 3,000 players on the waitlist to join its network across Africa. It is expected that Hulk Labs will continue to add hundreds of players each month and deploy further capital, with a target of getting to 10,000 players by the end of 2023.
Hulk continues to leverage its in-house software tools to scale its ability to manage a growing number of assets and players. In addition, in 2023, Hulk Labs will begin beta testing proprietary software that will connect its player network to interested investors, similar to how Uber connects passengers to drivers.
"Hulk Labs which has grown exponentially since its launch earlier this year and has sights on becoming one of the largest gaming guilds in the world," said Andrew Kiguel, CEO of Tokens.com. "Our partnerships in Africa successfully created new income opportunities leveraging the blockchain. We will continue to forge the business ahead and will be well equipped for when the crypto markets turn."
Hulk Labs is focused on three primary objectives. The first is identifying the best income-generation opportunities across the P2E economy by evaluating hundreds of the top P2E games and creating calculators to evaluate the profit potential and expected longevity of the games. Hulk Labs publishes many of these calculators at hulklabs.com for no cost.
Second, Hulk Labs buys P2E gaming assets (NFTs) that identify with the most profit potential and delegates them to a network of players in its network, located primarily in Africa.
Finally, the Company continues to build tools to streamline the delegation (sharing) and tracking of its P2E assets to various players. Hulk Labs has built tools to securely create and monitor thousands of cryptocurrency wallets, administer assets to these wallets while still maintaining custody of its assets, track player performance during gameplay, and streamline the transfer of tokens required for gameplay. The team is focused on scaling its products to support a wide variety of blockchains and games.
About Tokens.com
Tokens.com Corp is a publicly traded company that invests in web3 assets and builds web3 businesses. The Company focuses on three operating segments: i) crypto staking, ii) the metaverse and, iii) play-to-earn crypto gaming. Tokens.com owns digital assets and operating businesses within each of these three segments.
Staking operations occur within Tokens.com. Metaverse operations occur within a subsidiary called Metaverse Group. Crypto gaming operations occur within a subsidiary called Hulk Labs. All three businesses are tied together by the utilization of blockchain technology and are linked to high-growth macro trends within web3. Through sharing resources and infrastructure across these business segments, Tokens.com is able to efficiently incubate these businesses from inception to revenue generation.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities on Twitter, LinkedIn, and YouTube.
About Hulk Labs
Hulk Labs is a web3 technology company focused on building tools and systems to generate income from Play-to-Earn (P2E) blockchain games. Hulk Labs builds calculators to evaluate the profit potential and longevity of P2E games. In addition, the company is building a global player network to play games on behalf of asset-holders and is building tools to securely delegate and track in-game NFTs. Hulk Labs is a subsidiary of Tokens.com, a publicly- traded company that invests in web3 assets and businesses.
For further information please visit https://hulklabs.com.
Forward-looking Statements
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at https://www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221026005148/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media Contact: Ali Clarke – Talk Shop Media
Email: mailto://ali@talkshopmedia.com
NEWS -- Plus Therapeutics Announces Selection of “Rhenium (186Re) Obisbemeda” as International Non-Proprietary Name for 186RNL
AUSTIN, Texas, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that the World Health Organization’s (WHO) International Non-proprietary Name (INN) Expert Committee has selected the non-proprietary name “Rhenium (186Re) obisbemeda” for the Company’s lead investigational targeted radiotherapeutic, formerly known as 186RNL. Going forward, Plus Therapeutics will use Rhenium (186Re) obisbemeda in place of 186RNL.
“The assignment of Rhenium (186Re) obisbemeda as the recommended INN for 186RNL is another important milestone in the ongoing development of our lead targeted radiotherapeutic as we plan to move it towards mid- and late-stage clinical development, including a planned Phase 2 trial in patients with recurrent glioblastoma by the end of 2022,” said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics.
About Plus Therapeutics
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the development, manufacture, and commercialization of complex and innovative treatments for patients battling cancer and other life-threatening diseases. Our proprietary nanotechnology platform is currently centered around the enhanced delivery of a variety of drugs using novel liposomal encapsulation technology. Liposomal encapsulation has been extensively explored and undergone significant technical and commercial advances since it was first developed. Our platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at https://PlusTherapeutics.com and https://ReSPECT-Trials.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “designed to,” “will,” “can,” “potential,” “focus,” “preparing,” “next steps,” “possibly,” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of Rhenium (186Re) obisbemeda including the ability of Rhenium (186Re) obisbemeda to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company’s future performance including the next steps in developing the Company’s current assets; the Company’s clinical trials including statements regarding the timing and characteristics of the ReSPECT-GBM and ReSPECT-LM clinical trials; possible negative effects of Rhenium (186Re) obisbemeda; the continued evaluation of Rhenium (186Re) obisbemeda including through evaluations in additional patient cohorts; and the intended functions of the Company’s platform and expected benefits from such functions.
The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the Company’s actual results may differ, including materially, from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, the following: the early stage of the Company’s product candidates and therapies, the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash, the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field, among others; and additional risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor Contact
Peter Vozzo
ICR Westwicke
(443) 377-4767
mailto://Peter.Vozzo@westwicke.com
Media Contact
Terri Clevenger
ICR Westwicke
(203) 856-4326
mailto://Terri.Clevenger@westwicke.com
NEWS -- Provectus Biopharmaceuticals Expands Research Collaboration with The Rockefeller University to Investigate Clinical-Stage Immuno-Dermatology Agent PH-10 for Skin Inflammation
KNOXVILLE, TN, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has expanded its sponsored research program with James G. Krueger, MD, PhD, Co-director, Center for Clinical and Translational Science, D. Martin Carter Professor in Clinical Investigation, Senior Attending Physician, and head of the Laboratory of Investigative Dermatology at The Rockefeller University to investigate the potential for PH-10, a topical formulation of Provectus’ pharmaceutical-grade small molecule rose bengal sodium (RBS) drug substance, to directly alter the growth and differentiation of human keratinocytes, and to block cytokine-mediated signaling that creates different inflammatory skin diseases and may also be important in skin neoplasms.
PH-10 is an immuno-dermatology, multi-indication viable, clinical-stage pharmaceutical asset that the Company has used to treat more than 200 patients in multiple early- and mid-stage clinical trials for psoriasis and atopic dermatitis.
Dr. Krueger and the Laboratory of Investigative Dermatology plan to examine the effects of a wider range of PH-10 concentrations on human keratinocytes in vitro at the level of gene transcription. They also hope to determine PH-10’s interaction with and uptake by blood leukocytes, because these cells mediate inflammatory skin diseases and control or protect against some types of skin cancers.
The Kruger team previously elucidated several PH-10 mechanisms of action from work that it did as part of a Provectus clinical study of psoriasis, showing that:
NEWS -- Nighthawk Biosciences’ Scorpion Subsidiary Announces Grand Opening of its San Antonio Facility
DURHAM, N.C., Oct. 21, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that its Scorpion subsidiary plans to host the grand opening of its San Antonio facility today, October 21.
David Halverson, President of Scorpion, commented, “We are pleased with the recent FDA feedback regarding our design, operational strategy, and environmental controls relevant to clinical and commercial manufacturing at our San Antonio facility. In addition, the planning for our new facility in Manhattan, Kansas continues to progress. These two facilities, once fully operational, will provide Scorpion with substantial biomanufacturing capabilities to accommodate future worldwide demand for biologic manufacturing.”
The global pharmaceutical CDMO market is projected to reach $171 billion by 2026 from $120 billion in 20211. The industry currently suffers from a significant lack of capacity, resulting in meaningful delays and escalating costs.
The Company also reports its Scorpion subsidiary recently entered into a commercial contract to provide contract development and manufacturing services for a biopharmaceutical company to support development of their Phase 3 asset.
Jeff Wolf, CEO of Nighthawk, further noted, “We look forward to hosting the formal grand opening of our Scorpion San Antonio facility which represents an important milestone for the Company as we continue to execute on our strategy to develop a fully-integrated ecosystem that is designed to enable more rapid delivery of medical innovations with increased quality and efficiency.”
About Scorpion Biological Services
Scorpion Biological Services is a contract research, and contract development and manufacturing organization (CDMO) focused on cell- and gene-based therapies and large molecule biologics. Scorpion provides a broad array of clinical-scale biomanufacturing, analytical and R&D services to pharmaceutical and biotech companies from its San Antonio, Texas facilities. Scorpion also plans to offer commercial-scale biomanufacturing from its newly announced site in Manhattan, Kansas. Additional information is available at: https://www.scorpionbio.com/.
NightHawk Biosciences, Inc.
NightHawk Biosciences is a fully integrated biopharmaceutical company focused on the development of new drugs from discovery through commercialization. The Company leverages its integrated ecosystem of subsidiaries to accelerate the development of novel therapies that arm the immune system, breaking through barriers that prolong traditional drug development. This empowers us to bring our ideas to life with efficient control, superior quality, and uncharacteristic agility.
For more information on the Company and is subsidiaries, please visit: https://www.nighthawkbio.com, and follow us on Twitter.
Forward Looking Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, and include statements such as the Scorpion’s plans to host the grand opening of its San Antonio facility on October 21, planning for our new facility in Manhattan, Kansas continues to progress, the two facilities, once fully operational, providing Scorpion with substantial biomanufacturing capabilities to accommodate future worldwide demand for biologic manufacturing the global pharmaceutical CDMO market being projected to reach $171 billion by 2026 from $120 billion in 2021, and continuing to execute on the Company’s strategy to develop a fully-integrated ecosystem that is designed to enable more rapid delivery of medical innovations with increased quality and efficiency. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability to open the San Antonio facility and Kansas facility when planned, the ability of Scorpion to accommodate future worldwide demand for biologic manufacturing the global pharmaceutical CDMO market, the size of the global pharmaceutical CDMO market, the ability to develop a fully-integrated ecosystem that is designed to enable more rapid delivery of medical innovations with increased quality and efficiency, , the ability of Scorpion to leverage its biologic manufacturing capabilities, whether the combined business of NightHawk and Elusys will be successful, NightHawk’s ability to successfully operate as a CDMO, NightHawk’s and its subsidiaries’ ability to maintain license agreements, the continued maintenance and growth of NightHawk’s and its subsidiaries’ patent estates, NightHawk’s product candidates demonstrating safety and effectiveness, as well as results that are consistent with prior results, the ability to initiate clinical trials and if initiated, the ability to complete them on time and achieve the desired results and benefits continuing enrollment as expected, the ability to obtain regulatory approval for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to NightHawk’s ability to promote or commercialize its product candidates for the specific indications, acceptance of product candidates in the marketplace and the successful development, marketing or sale of NightHawk’s products, developments by competitors that render such products obsolete or non-competitive, and other factors described in NightHawk’s annual report on Form 10-K for the year ended December 31, 2021, subsequent quarterly reports on Form 10-Qs and any other filings NightHawk makes with the SEC. The information in this presentation is provided only as of the date presented, and NightHawk undertakes no obligation to update any forward-looking statements contained in this presentation on account of new information, future events, or otherwise, except as required by law.
Media and Investor Relations Contact
David Waldman
+1 919 289 4017
mailto://investorrelations@heatbio.com
_________________________
1 https://www.marketsandmarkets.com/Market-Reports/pharmaceutical-contract-manufacturing-market-201524381.html?gclid=Cj0KCQjw_viWBhD8ARIsAH1mCd5GN2FB5wstsuUSbLcWUnl5ESygiO41tyZjJ3e990Qwh_uJsLC472gaAi89EALw_wcB
NEWS -- Nanomix Enters into Distribution Agreement for the eLab System with Diaclinic SpA in Chile
SAN LEANDRO, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Nanomix Corporation (OTCQB: NNMX) (“Nanomix” or the “Company”), a leader in the development of mobile, affordable, point-of-care (POC) diagnostics, today announced a new distribution agreement with Diaclinic SpA (“Diaclinic”), a medical distributor headquartered in Santiago, Chile. Diaclinic will market and distribute the Nanomix eLab in the Republic of Chile.
“We continue to expand our footprint internationally and gain strategic regions due to the unique benefits of the eLab system,” stated Thomas Schlumpberger, Chief Executive Officer of Nanomix. “In approximately 12 minutes, the eLab system can provide healthcare professionals accurate and quantitative results without sending samples to a central lab. Time to diagnosis is critical for patients in sepsis, getting appropriate treatment right away leads to vastly improved survival rates. Additionally, first responders and other healthcare providers can use the eLab for quick, on-the-spot assessment and triage of patients no matter where they are.”
John Hardesky, Chief Commercial Officer of Nanomix, commented, “Chile is a fantastic point of entry for expansion into Latin America. We are looking forward to our collaboration with Diaclinic and making an impact in Chile while supporting clinicians in the fight against critical infections and sepsis. We remain laser focused on accomplishing our near-term goal of distribution expansion into new regions and market segments.”
Sepsis is a recognized global health crisis. Early identification and treatment is a need and a challenge for healthcare professionals around the globe. For many reasons, sepsis can be difficult to identify and is frequently under-diagnosed in the earliest stages. It affects as many as 50 million people every year, leading to approximately 11 million deaths annually.
The Nanomix eLab® system is a mobile, hand-held immunoassay and chemistry diagnostic system designed for the needs of rapid point-of-care testing. The Nanomix eLab® system offers a variety of benefits, including results in minutes, lower cost, and portability, while providing accurate, quantitative results comparable in quality to those provided by central lab testing. Furthermore, the S1 Panel Cartridge was developed as an aid in rapidly diagnosing critical infections including sepsis. The panel provides quantitative test results for procalcitonin (PCT), C-reactive protein (CRP) and lactate (LAC) from a single venous whole blood or plasma sample type. The assay runs on the eLab® Analyzer with results available in approximately 12 minutes from sample to answer, versus the current diagnostic solutions which can take hours to provide a test result. The S1 Panel assay has received the CE marking in Europe and has UK Medicines and Healthcare products Regulatory Agency (MHRA) registration.
About Diaclinic SpA
Diaclinic is a distribution company in Chile currently representing various medical products and devices to Chile markets including private and public clinical entities. Diaclinic is led by Carlos Jimenez S. who has established successful businesses in this area and who also serves as the Director General for Microbac SpA in Chile.
About Nanomix Corporation
Nanomix (OTCQB: NNMX) is developing mobile point-of-care diagnostics with its Nanomix eLab® System platform and assays that provide rapid, accurate, quantitative information for use in settings where time is critical to clinical decision-making and improved patient care. The company’s products are designed to broadly impact healthcare delivery by bringing diagnostics to the point of initial patient interaction, whether in the hospital or in pre-hospital, remote or alternate-care settings, thereby enabling faster clinical decision-making and potentially treatment-in-place. Nanomix’s first assays address the need for faster diagnosis of critical infections including sepsis. The company is developing a pipeline of other tests designed to improve patient outcomes by making high-quality diagnostic information available within minutes. For more information, visit https://www.nanomixdx.com.
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Forward looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company’s ongoing and planned product development; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Natalya Rudman
Crescendo Communications, LLC
Email: mailto://NNMX@crescendo-ir.com ;
Tel: (212) 671-1020 Ext.304
NEWS -- FuelPositive Presents its Green Ammonia Technology to Canada UK Energy Summit in London UK
TORONTO, Oct. 20, 2022 (GLOBE NEWSWIRE) -- FuelPositive Corporation (TSX.V: NHHH) (OTCQB: NHHHF) (“FuelPositive” or the “Company”) is pleased to report it attended and addressed the delegates at the 13th Annual Canada UK Energy Summit held yesterday at Canada House in London, UK. With a focus on industrial decarbonization, the aim of the annual summit is to expand export opportunities for Canadian firms into the UK market and strengthen bilateral commercial cooperation. One hundred Canadian and UK pre-qualified company representatives participated, along with 25 Canadian and British government representatives who are responsible for the advancement of policy and funding frameworks. FuelPositive was one of five Canadian emerging technology companies invited to address the entire group in the Innovators Session.
“We were delighted that our technology and company are being recognized by government leaders as a valuable tool in the fight against climate change. Our onsite, containerized green ammonia production system is a perfect example of a practical, decentralized and economical approach to industrial decarbonization. It disrupts the traditional, centralized grey ammonia industry, that’s driven by fossil fuels and is well known as a major polluter around the world. Our system produces carbon-free, green ammonia using air, water and sustainable electricity, and the decentralized, onsite model allows end-users to produce the ammonia they need for fertilizer and/or for fuel on their own land, where the ammonia is going to be used. That means we’ve eliminated carbon emissions from the production process of ammonia, and we’ve eliminated the need for large storage facilities and the transportation of dirty ammonia across vast distances to end users,” said Ian Clifford, FuelPositive CEO and Board Chair.
FuelPositive’s first demonstration system is expected to be fully validated and farm-ready in November 2022, before being moved to an 11,000-acre farm in Manitoba where it will be run for one year in all types of weather as a pilot project. The Company has begun to accept pre-sales inquiries. The onsite model provides end users with stability and control over supply, timing and price.
Grey Ammonia and Pollution
Over 200 million tonnes of traditional or grey ammonia are manufactured and consumed annually worldwide. In fact, grey ammonia currently ranks as the second most produced chemical globally, with production accounting for two per cent of the world’s fossil fuel use. Eighty per cent of grey ammonia is used as nitrogen fertilizer to grow food. While we rely on ammonia as fertilizer for food security, the traditional method of producing it, in massive, centralized refineries, is one of the most emissions-intensive manufacturing processes in the world. As a whole, the traditional ammonia industry generates over 420 million tons of carbon dioxide annually. For every metric tonne of traditional or grey ammonia produced globally, almost three metric tonnes of greenhouse gases are emitted.
Supply Shortages and Skyrocketing Prices
The centralized model of traditional ammonia manufacturing has also created significant problems in the form of supply shortages and skyrocketing prices. A relatively small number of refineries provide all the ammonia used around the planet. The ammonia must be transported vast distances from the point of production to the point of use. That supply chain has been unreliable for several years because of hurricanes, fossil fuel shortages, the COVID-19 pandemic, and now Russia’s tragic war in Ukraine. Farmers, for example, never know exactly when they will get their delivery, how much they will get, and how much they will have to pay. Prices have risen to the point that grey ammonia is unaffordable for many. And with the war in Ukraine, it continues to get worse, given the amount of food, fertilizer and fuel annually supplied by Ukraine and Russia.
About FuelPositive
FuelPositive is a Canadian technology company committed to providing commercially viable and sustainable, “cradle to cradle”, clean technology solutions, including an on-site, containerized green ammonia (NH3) production system that eliminates carbon emissions from the production of the green ammonia. By focusing on technologies that are clean, sustainable and economically advantageous/realizable, the Company aims to change the course of climate change through practical solutions that can be implemented in the short term.
The FuelPositive onsite, containerized green ammonia production system produces pure, anhydrous ammonia for multiple applications, including fertilizer for farming, fuel for grain drying and internal combustion engines, a practical alternative for fuel cells and a solution for grid storage. Green ammonia is also considered a key enabler of the hydrogen economy. The system comprises a nitrogen generator to produce nitrogen from air, a water electrolyser to produce hydrogen from water, and a patent-pending synthesis converter to produce green ammonia from the hydrogen and nitrogen.
FuelPositive systems are designed to provide for green ammonia production on-site, where it’s needed. This eliminates wildly fluctuating supply chains and offers end-users energy and supply security, as well as stable prices, while cutting carbon emissions from the production process. The first customers will be farmers. Farmers use 80% of the traditional ammonia produced today as fertilizer.
Cautionary Statement
Trading in the securities of the Company should be considered highly speculative. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains certain “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) that are based on expectations, estimates and projections as of the date of this news release. The information in this release about future plans and objectives of the Company, including the expected expenditures of the proceeds of the private placement, are forward-looking statements.
These forward-looking statements are based on assumptions and estimates of management of the Company at the time they were made and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect.
Many of these uncertainties and contingencies can directly or indirectly affect and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
Forward-looking information is provided for the purpose of providing information about management’s expectations and plans relating to the future. The Company disclaims any intention or obligation to update or revise any forward-looking information or to explain any material difference between subsequent actual events and such forward-looking information, except to the extent required by applicable law.
For Investor enquiries, please contact:
Ian Clifford
Chief Executive Officer and Board Chair
mailto://info@fuelpositive.com
https://www.fuelpositive.com
Investor Relations (United States)
RBMG – RB Milestone Group LLC
Trevor Brucato, Managing Director
mailto://fuelpositive@rbmilestone.com
https://www.rbmilestone.com
For Media enquiries, please contact:
Oliveah Numan
Sussex Strategy Group
519-770-2991
mailto://onuman@sussex-strategy.com
NEWS -- Tokens.com Secures Partnership with Aftermath Islands
TORONTO, October 19, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN)(Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), a publicly-traded company that invests in web3 assets and builds businesses linked to crypto staking, the metaverse and play-to-earn gaming, is pleased to announce that its subsidiary, Metaverse Group, has signed a partnership agreement with Aftermath Islands Limited, a controlled subsidiary of Liquid Avatar Technologies (CSE: LQID / OTC: LQAVF / FRA: 4T51).
Aftermath Islands has granted Metaverse Group three islands in its Metaverse. The Aftermath Islands Metaverse is being built as an open-world, realistic graphics platform with islands that represent destinations in a global virtual game, with Pixel Streaming, no download and Proof of Humanity for its users. Metaverse Group can develop its islands with luxury establishments, marinas, concert venues, or other new exciting possibilities for brands and businesses. The establishment of this partnership is another step in bringing new brands and companies to life in web3. The companies will work together to find the best activations for the Unreal Engine 5 graphics being used in Aftermath Islands.
In addition to partnering with Aftermath Islands, Metaverse Group has partnered with Renovi to develop the metaverse’s first buildathon competition for architects, 3D designers and developers.
The competition, part of ‘Next Top Metaverse Build’, is encouraging university students, architects, and design professionals from around the world to create a variety of digital infrastructure, wearables and furniture intended for metaverse residential, retail, clubhouse and venue spaces. Entrants will need to work with Unreal Engine 5 to submit their builds - encouraging creators to develop designs that are similar to high-quality gaming for use in Aftermath Islands.
Competitors will have the opportunity to win a suite of prizes across various categories including $50,000 in land parcels, strong boxes (in-game tokens), gift cards, the ability to sell their creations as NFTs in collaboration with Aftermath Islands and more. The competition is open for entries until January 9, 2023 at 5pm GMT. Winners will be chosen by the judges including Metaverse Groups’ very own Hetal Petal, Aftermath Islands’ technology specialist Rob Cole and managing director David Lucatch; Renovi co-founder Adonis Zachariades; and president of VRchitect, Cherie Bowker.
"As leaders in metaverse development, it is crucial for us to be attracting talent from across the world to add innovation and spark to these new worlds," commented Lorne Sugarman, CEO of Metaverse Group. "By supporting buildathon competitions not only are we helping advance web3 infrastructure and development, but we are also introducing new design possibilities to our clients with the most creative and advanced creations seen in the space."
"We are excited to partner with Metaverse Group to further develop the Aftermath Islands community," said David Lucatch, CEO of Liquid Avatar Technologies & Managing Director of Aftermath Islands Metaverse. "We have seen Metaverse Group launch multiple reputable brands into metaverses, and we are looking forward to showcasing new builds via the Buildathon in our metaverse to help attract new business."
The first Next Top Metaverse Buildathon took place earlier this year and saw 250 creators submit more than 160 entries, with $200,000 in prizes distributed to date.
"This Buildathon is aimed at showcasing the Aftermath Islands metaverse and seeing what creators can build for it," said Adonis Zachariades, Co-founder at Renovi. "We’re looking forward to seeing how innovative designers create their 3D buildings, wearables or even furniture this time. This is the ideal opportunity to put their talents to the test. Winning designs will be shared by Aftermath Islands and Renovi before we drop the creations in our special buildathon collection on Aftermath Islands Marketplace."
For more information and contest rules please visit https://www.Topmetaversebuild.com.
About Tokens.com
Tokens.com Corp is a publicly traded company that invests in web3 assets and builds web3 businesses. The Company focuses on three operating segments: i) crypto staking, ii) the metaverse and, iii) play-to-earn crypto gaming. Tokens.com owns digital assets and operating businesses within each of these three segments.
Staking operations occur within Tokens.com. Metaverse operations occur within a subsidiary called Metaverse Group. Crypto gaming operations occur within a subsidiary called Hulk Labs. All three businesses are tied together by the utilization of blockchain technology and are linked to high-growth macro trends within web3. Through sharing resources and infrastructure across these business segments, Tokens.com is able to efficiently incubate these businesses from inception to revenue generation.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities on Twitter, LinkedIn, and YouTube.
About Metaverse Group
Metaverse Group is a web3 technology company with products and services that bring businesses to life in web3 environments, including metaverses, NFTs and the next iteration of retail, ecomm3. We integrate web3 technology solutions with a web3 marketing agency and virtual real estate development services, so that our clients can own ecomm3, engage new audiences, and be first movers. The company also holds an eight-figure metaverse real estate portfolio spanning over 10+ metaverses.
Our ownership over 750 parcels of virtual land and relationships with different metaverses and industry players allow us to deliver category leading solutions that have been recognized by CNBC, Forbes, the Economist and the Wall Street Journal. Tokens.com, a publicly- traded company, is the majority owner of Metaverse Group.
For further information please visit https://metaversegroup.com.
About Aftermath Islands
Aftermath Islands is a blockchain-based virtual reality interactive platform, consisting of theme-based islands, communities, and estates. Users can buy, develop, and trade virtual land, property and items as NFTs.
For more information visit https://aftermathislands.com
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221019005230/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media Contact: Ali Clarke – Talk Shop Media
Email: mailto://ali@talkshopmedia.com
NEWS -- Tokens.com Secures Partnership with Aftermath Islands
TORONTO, October 19, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN)(Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), a publicly-traded company that invests in web3 assets and builds businesses linked to crypto staking, the metaverse and play-to-earn gaming, is pleased to announce that its subsidiary, Metaverse Group, has signed a partnership agreement with Aftermath Islands Limited, a controlled subsidiary of Liquid Avatar Technologies (CSE: LQID / OTC: LQAVF / FRA: 4T51).
Aftermath Islands has granted Metaverse Group three islands in its Metaverse. The Aftermath Islands Metaverse is being built as an open-world, realistic graphics platform with islands that represent destinations in a global virtual game, with Pixel Streaming, no download and Proof of Humanity for its users. Metaverse Group can develop its islands with luxury establishments, marinas, concert venues, or other new exciting possibilities for brands and businesses. The establishment of this partnership is another step in bringing new brands and companies to life in web3. The companies will work together to find the best activations for the Unreal Engine 5 graphics being used in Aftermath Islands.
In addition to partnering with Aftermath Islands, Metaverse Group has partnered with Renovi to develop the metaverse’s first buildathon competition for architects, 3D designers and developers.
The competition, part of ‘Next Top Metaverse Build’, is encouraging university students, architects, and design professionals from around the world to create a variety of digital infrastructure, wearables and furniture intended for metaverse residential, retail, clubhouse and venue spaces. Entrants will need to work with Unreal Engine 5 to submit their builds - encouraging creators to develop designs that are similar to high-quality gaming for use in Aftermath Islands.
Competitors will have the opportunity to win a suite of prizes across various categories including $50,000 in land parcels, strong boxes (in-game tokens), gift cards, the ability to sell their creations as NFTs in collaboration with Aftermath Islands and more. The competition is open for entries until January 9, 2023 at 5pm GMT. Winners will be chosen by the judges including Metaverse Groups’ very own Hetal Petal, Aftermath Islands’ technology specialist Rob Cole and managing director David Lucatch; Renovi co-founder Adonis Zachariades; and president of VRchitect, Cherie Bowker.
"As leaders in metaverse development, it is crucial for us to be attracting talent from across the world to add innovation and spark to these new worlds," commented Lorne Sugarman, CEO of Metaverse Group. "By supporting buildathon competitions not only are we helping advance web3 infrastructure and development, but we are also introducing new design possibilities to our clients with the most creative and advanced creations seen in the space."
"We are excited to partner with Metaverse Group to further develop the Aftermath Islands community," said David Lucatch, CEO of Liquid Avatar Technologies & Managing Director of Aftermath Islands Metaverse. "We have seen Metaverse Group launch multiple reputable brands into metaverses, and we are looking forward to showcasing new builds via the Buildathon in our metaverse to help attract new business."
The first Next Top Metaverse Buildathon took place earlier this year and saw 250 creators submit more than 160 entries, with $200,000 in prizes distributed to date.
"This Buildathon is aimed at showcasing the Aftermath Islands metaverse and seeing what creators can build for it," said Adonis Zachariades, Co-founder at Renovi. "We’re looking forward to seeing how innovative designers create their 3D buildings, wearables or even furniture this time. This is the ideal opportunity to put their talents to the test. Winning designs will be shared by Aftermath Islands and Renovi before we drop the creations in our special buildathon collection on Aftermath Islands Marketplace."
For more information and contest rules please visit https://www.Topmetaversebuild.com.
About Tokens.com
Tokens.com Corp is a publicly traded company that invests in web3 assets and builds web3 businesses. The Company focuses on three operating segments: i) crypto staking, ii) the metaverse and, iii) play-to-earn crypto gaming. Tokens.com owns digital assets and operating businesses within each of these three segments.
Staking operations occur within Tokens.com. Metaverse operations occur within a subsidiary called Metaverse Group. Crypto gaming operations occur within a subsidiary called Hulk Labs. All three businesses are tied together by the utilization of blockchain technology and are linked to high-growth macro trends within web3. Through sharing resources and infrastructure across these business segments, Tokens.com is able to efficiently incubate these businesses from inception to revenue generation.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities on Twitter, LinkedIn, and YouTube.
About Metaverse Group
Metaverse Group is a web3 technology company with products and services that bring businesses to life in web3 environments, including metaverses, NFTs and the next iteration of retail, ecomm3. We integrate web3 technology solutions with a web3 marketing agency and virtual real estate development services, so that our clients can own ecomm3, engage new audiences, and be first movers. The company also holds an eight-figure metaverse real estate portfolio spanning over 10+ metaverses.
Our ownership over 750 parcels of virtual land and relationships with different metaverses and industry players allow us to deliver category leading solutions that have been recognized by CNBC, Forbes, the Economist and the Wall Street Journal. Tokens.com, a publicly- traded company, is the majority owner of Metaverse Group.
For further information please visit https://metaversegroup.com.
About Aftermath Islands
Aftermath Islands is a blockchain-based virtual reality interactive platform, consisting of theme-based islands, communities, and estates. Users can buy, develop, and trade virtual land, property and items as NFTs.
For more information visit https://aftermathislands.com
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221019005230/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media Contact: Ali Clarke – Talk Shop Media
Email: mailto://ali@talkshopmedia.com
NEWS -- Plus Therapeutics Presents Preliminary Safety and Feasibility Data from ReSPECT-LM Clinical Trial at the European Association of Nuclear Medicine Congress
ReSPECT-LM Phase 1 clinical trial selected as TOP Trials Oral Presentation
Treatment was well tolerated without dose limiting toxicities and all patients showed a decrease in spinal fluid tumor cell counts
ReSPECT-GBM Phase 1 clinical data selected as Top-Rated Oral Presentation and inclusion in opening Highlights Lecture
AUSTIN, Texas, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, presented data from two ongoing clinical trials evaluating the Company’s lead investigational targeted radiotherapeutic, Rhenium-186 NanoLiposome (186RNL), in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM) at the 35th Annual Congress of the European Association of Nuclear Medicine (EANM). The Company’s ReSPECT-GBM presentation was selected for inclusion in the opening Plenary Highlights Lecture, signaling significant clinical interest in the field.
“The findings presented at EANM indicate the potential for 186RNL in patients diagnosed with leptomeningeal metastases,” said Norman LaFrance, M.D., Chief Medical Officer and Senior Vice President at Plus Therapeutics. “Combined with our Phase 1 data in recurrent glioblastoma, these presentations reinforce the tremendous potential of 186RNL as a versatile radiotherapeutic treatment option for multiple CNS cancers.”
The TOP Trials Oral Presentation titled, Safety and Feasibility of Rhenium-186 Nanoliposome (186RNL) in Leptomeningeal Metastases (LM) Phase 1 dose escalation Trial [OP-759], demonstrated:
NEWS -- Tokens.com Announces Fiscal Year-End Change
TORONTO, October 18, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN)(Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or the "Company"), a publicly-traded company that invests in web3 assets and builds businesses linked to crypto staking, the metaverse and play-to-earn gaming, today announces that it is changing its fiscal year-end from December 31 to September 30.
The Company is changing its year-end to better facilitate the audit process given the significant demand it has observed in recent years for audit services for companies that have a year-end of December 31. As a result, the Company expects to file its audited nine-month fiscal year ended September 30, 2022 financial statements in mid-December 2022.
For more details regarding the length and ending dates of the financial periods, including the comparative periods of the interim and annual financial statements to be filed for the Company’s transition year and its new financial year, reference is made to the Notice of Change in Year-End required under Section 4.8 of National Instrument 51-102 that has been filed under the Company’s profile at https://www.sedar.com.
About Tokens.com
Tokens.com Corp is a publicly traded company that invests in web3 assets and builds web3 businesses. The Company focuses on three operating segments: i) crypto staking, ii) the metaverse and, iii) play-to-earn crypto gaming. Tokens.com owns digital assets and operating businesses within each of these three segments.
Staking operations occur within Tokens.com. Metaverse operations occur within a subsidiary called Metaverse Group. Crypto gaming operations occur within a subsidiary called Hulk Labs. All three businesses are tied together by the utilization of blockchain technology and are linked to high-growth macro trends within web3. Through sharing resources and infrastructure across these business segments, Tokens.com is able to efficiently incubate these businesses from inception to revenue generation.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities on Twitter, LinkedIn, and YouTube.
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at https://www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221018005253/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media Contact: Ali Clarke – Talk Shop Media
Email: mailto://ali@talkshopmedia.com
NEWS -- Tokens.com Announces Fiscal Year-End Change
TORONTO, October 18, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN)(Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or the "Company"), a publicly-traded company that invests in web3 assets and builds businesses linked to crypto staking, the metaverse and play-to-earn gaming, today announces that it is changing its fiscal year-end from December 31 to September 30.
The Company is changing its year-end to better facilitate the audit process given the significant demand it has observed in recent years for audit services for companies that have a year-end of December 31. As a result, the Company expects to file its audited nine-month fiscal year ended September 30, 2022 financial statements in mid-December 2022.
For more details regarding the length and ending dates of the financial periods, including the comparative periods of the interim and annual financial statements to be filed for the Company’s transition year and its new financial year, reference is made to the Notice of Change in Year-End required under Section 4.8 of National Instrument 51-102 that has been filed under the Company’s profile at https://www.sedar.com.
About Tokens.com
Tokens.com Corp is a publicly traded company that invests in web3 assets and builds web3 businesses. The Company focuses on three operating segments: i) crypto staking, ii) the metaverse and, iii) play-to-earn crypto gaming. Tokens.com owns digital assets and operating businesses within each of these three segments.
Staking operations occur within Tokens.com. Metaverse operations occur within a subsidiary called Metaverse Group. Crypto gaming operations occur within a subsidiary called Hulk Labs. All three businesses are tied together by the utilization of blockchain technology and are linked to high-growth macro trends within web3. Through sharing resources and infrastructure across these business segments, Tokens.com is able to efficiently incubate these businesses from inception to revenue generation.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities on Twitter, LinkedIn, and YouTube.
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at https://www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221018005253/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media Contact: Ali Clarke – Talk Shop Media
Email: mailto://ali@talkshopmedia.com
NEWS -- Plus Therapeutics to Present at the ThinkEquity Conference
AUSTIN, Texas, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, announced today that Marc Hedrick, M.D., President and Chief Executive Officer, will present at the ThinkEquity Conference on Wednesday, October 26, 2022, at 3:00 p.m. ET, and host investor meetings. The conference is being held at the Mandarin Oriental, New York in New York City.
Investors interested in arranging a meeting with the Company’s management during the conference should contact the conference coordinator. An archived replay of the presentation will be available under the Events tab of the Plus Therapeutics website at https://www.plustherapeutics.com for 90 days following the event.
About Plus Therapeutics
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the development, manufacture, and commercialization of complex and innovative treatments for patients battling cancer and other life-threatening diseases. Our proprietary nanotechnology platform is currently centered around the enhanced delivery of a variety of drugs using novel liposomal encapsulation technology. Liposomal encapsulation has been extensively explored and undergone significant technical and commercial advances since it was first developed. Our platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at https://PlusTherapeutics.com and https://ReSPECT-Trials.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “designed to,” “will,” “can,” “potential,” “focus,” “preparing,” “next steps,” “possibly,” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of 186RNL including the ability of 186RNL to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company’s future performance including the next steps in developing the Company’s current assets; the Company’s clinical trials including statements regarding the timing and characteristics of the ReSPECT-GBM and ReSPECT-LM clinical trials; possible negative effects of 186RNL; the continued evaluation of 186RNL including through evaluations in additional patient cohorts; and the intended functions of the Company’s platform and expected benefits from such functions.
The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the Company’s actual results may differ, including materially, from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, the following: the early stage of the Company’s product candidates and therapies, the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash, the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field, among others; and additional risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor Contact
Peter Vozzo
ICR Westwicke
(443) 377-4767
mailto://Peter.Vozzo@westwicke.com
Media Contact
Terri Clevenger
ICR Westwicke
(203) 856-4326
mailto://Terri.Clevenger@westwicke.com
NEWS -- Tokens.com Announces Full Occupancy of its Digital Real Estate in Decentraland’s Downtown and Fashion District
TORONTO, October 11, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN)(Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), a publicly-traded company that invests in web3 assets and builds businesses linked to crypto staking, the metaverse and play-to-earn gaming, is pleased to announce that its subsidiary, Metaverse Group, has fully leased its digital real estate in two popular Decentraland neighborhoods. The land is occupied by a diverse collection of esteemed brands and businesses, including Forever 21, Skechers, and McCann Global.
Metaverse Group is a web3 technology company holding an eight-figure metaverse real estate portfolio spanning over 10+ metaverses. The company leases its land to brands and businesses who are looking to enter web3, pairing the offering with strategic consultation and technology.
Metaverse Group has leased out a total of 208 virtual real estate, equivalent to over 560,000 square feet of flat land, across its Fashion Street Estate and Downtown Decentraland properties. In addition to leasing the Company’s virtual land, the majority of tenants also used Metaverse Group for design and development services.
Metaverse Group’s client portfolio includes over 60 notable fashion brands such as Skechers, the third largest athletic footwear brand in the United States; Forever 21, a multinational fashion leader; and Space Runners who design and launch digital wearable NFTs for metaverses in collaboration with celebrities and brands, Miami Fashion Week which is the world's first fashion week to simultaneous launch a digital and physical fashion week. Clients also include media companies such as Deutsch LA, BSC News, McCann Global, and Coffee WW. Clients also include service providers such as Sophia Technologies, an online education platform; Schneider Electric; an industrial automation company and Groundbreak Ventures LP; a venture capital firm specializing in real estate and property technology.
"The full occupancy of this portion of our portfolio solidifies our position as early supporters, adopters and developers of the web3 community," said Lorne Sugarman, CEO of Metaverse Group. "It is our job to provide the best experience for our clients when we launch them into this new world, as this supports the growth of web3. We have been working hard developing these areas and cannot wait to share more advancements in the near future."
Metaverse Group provides an assortment of white glove services to launch clients into the metaverse and the world of web3 from the beginning of project consulting to project completion. Brands and businesses who are interested in launching a metaverse presence are encouraged to contact mailto://info@metaversegroup.com.
About Tokens.com
Tokens.com Corp is a publicly traded company that invests in web3 assets and builds web3 businesses. The Company focuses on three operating segments: i) crypto staking, ii) the metaverse and, iii) play-to-earn crypto gaming. Tokens.com owns digital assets and operating businesses within each of these three segments.
Staking operations occur within Tokens.com. Metaverse operations occur within a subsidiary called Metaverse Group. Crypto gaming operations occur within a subsidiary called Hulk Labs. All three businesses are tied together by the utilization of blockchain technology and are linked to high-growth macro trends within web3. Through sharing resources and infrastructure across these business segments, Tokens.com is able to efficiently incubate these businesses from inception to revenue generation.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities on Twitter, LinkedIn, and YouTube.
About Metaverse Group
Metaverse Group is a web3 technology company with products and services that bring businesses to life in web3 environments, including metaverses, NFTs and the next iteration of retail, ecomm3. We integrate web3 technology solutions with a web3 marketing agency and virtual real estate development services, so that our clients can own ecomm3, engage new audiences, and be first movers. The company also holds an eight-figure metaverse real estate portfolio spanning over 10+ metaverses.
Our ownership over 750 parcels of virtual land and relationships with different metaverses and industry players allow us to deliver category leading solutions that have been recognized by CNBC, Forbes, the Economist and the Wall Street Journal. Tokens.com, a publicly- traded company, is the majority owner of Metaverse Group.
For further information please visit https://metaversegroup.com.
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at https://www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221011005105/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media Contact: Ali Clarke – Talk Shop Media
Email: mailto://ali@talkshopmedia.com
NEWS -- Tokens.com Announces Full Occupancy of its Digital Real Estate in Decentraland’s Downtown and Fashion District
TORONTO, October 11, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN)(Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), a publicly-traded company that invests in web3 assets and builds businesses linked to crypto staking, the metaverse and play-to-earn gaming, is pleased to announce that its subsidiary, Metaverse Group, has fully leased its digital real estate in two popular Decentraland neighborhoods. The land is occupied by a diverse collection of esteemed brands and businesses, including Forever 21, Skechers, and McCann Global.
Metaverse Group is a web3 technology company holding an eight-figure metaverse real estate portfolio spanning over 10+ metaverses. The company leases its land to brands and businesses who are looking to enter web3, pairing the offering with strategic consultation and technology.
Metaverse Group has leased out a total of 208 virtual real estate, equivalent to over 560,000 square feet of flat land, across its Fashion Street Estate and Downtown Decentraland properties. In addition to leasing the Company’s virtual land, the majority of tenants also used Metaverse Group for design and development services.
Metaverse Group’s client portfolio includes over 60 notable fashion brands such as Skechers, the third largest athletic footwear brand in the United States; Forever 21, a multinational fashion leader; and Space Runners who design and launch digital wearable NFTs for metaverses in collaboration with celebrities and brands, Miami Fashion Week which is the world's first fashion week to simultaneous launch a digital and physical fashion week. Clients also include media companies such as Deutsch LA, BSC News, McCann Global, and Coffee WW. Clients also include service providers such as Sophia Technologies, an online education platform; Schneider Electric; an industrial automation company and Groundbreak Ventures LP; a venture capital firm specializing in real estate and property technology.
"The full occupancy of this portion of our portfolio solidifies our position as early supporters, adopters and developers of the web3 community," said Lorne Sugarman, CEO of Metaverse Group. "It is our job to provide the best experience for our clients when we launch them into this new world, as this supports the growth of web3. We have been working hard developing these areas and cannot wait to share more advancements in the near future."
Metaverse Group provides an assortment of white glove services to launch clients into the metaverse and the world of web3 from the beginning of project consulting to project completion. Brands and businesses who are interested in launching a metaverse presence are encouraged to contact mailto://info@metaversegroup.com.
About Tokens.com
Tokens.com Corp is a publicly traded company that invests in web3 assets and builds web3 businesses. The Company focuses on three operating segments: i) crypto staking, ii) the metaverse and, iii) play-to-earn crypto gaming. Tokens.com owns digital assets and operating businesses within each of these three segments.
Staking operations occur within Tokens.com. Metaverse operations occur within a subsidiary called Metaverse Group. Crypto gaming operations occur within a subsidiary called Hulk Labs. All three businesses are tied together by the utilization of blockchain technology and are linked to high-growth macro trends within web3. Through sharing resources and infrastructure across these business segments, Tokens.com is able to efficiently incubate these businesses from inception to revenue generation.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities on Twitter, LinkedIn, and YouTube.
About Metaverse Group
Metaverse Group is a web3 technology company with products and services that bring businesses to life in web3 environments, including metaverses, NFTs and the next iteration of retail, ecomm3. We integrate web3 technology solutions with a web3 marketing agency and virtual real estate development services, so that our clients can own ecomm3, engage new audiences, and be first movers. The company also holds an eight-figure metaverse real estate portfolio spanning over 10+ metaverses.
Our ownership over 750 parcels of virtual land and relationships with different metaverses and industry players allow us to deliver category leading solutions that have been recognized by CNBC, Forbes, the Economist and the Wall Street Journal. Tokens.com, a publicly- traded company, is the majority owner of Metaverse Group.
For further information please visit https://metaversegroup.com.
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at https://www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221011005105/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media Contact: Ali Clarke – Talk Shop Media
Email: mailto://ali@talkshopmedia.com
NEWS -- Lineage Announces Notice of Allowance of Two Patents Covering Processes for Manufacturing Allogeneic Oligodendrocyte Progenitor and Retinal Pigmented Epithelium Cells
CARLSBAD, Calif., October 10, 2022--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance to grant a patent for the Company’s U.S. patent application No. 16/750,975, entitled "Dorsally-Derived Oligodendrocyte Progenitor Cells From Human Pluripotent Stem Cells," with claims covering proprietary manufacturing processes developed by Lineage for its oligodendrocyte progenitor cell therapy candidate (OPC1) for the treatment of spinal cord injury (SCI). The patent, which is expected to be issued in the coming months, would have a term that would expire no earlier than 2040. Additionally, the Company announced that the European Patent Office (EPO) has issued a notice of Intention to Grant a patent for Lineage’s patent application entitled "Preparation of Retinal Pigment Epithelium Cells," (European Patent Application 16753990.7).
"These new patents highlight our ability to generate differentiated cell types from undifferentiated pluripotent cells and are valuable outputs from our platform. The production of specific cell lineages in a controlled and reproducible manner, on platforms which can support large-scale clinical trials, provide us with an important competitive advantage," stated Brian M. Culley, Lineage CEO. "In addition to extending the patent coverage of our assets, new IP can also permit us to protect our programs without relying on patents licensed or obtained from third parties, which may reduce or eliminate payments to such third parties and retain more value for Lineage."
Lineage aims to provide cell-based therapeutic benefits to patients by replacing cells lost due to disease, aging, or in the case of spinal cord injury, a traumatic event. The Company currently is focused on preparing for a planned interaction with the U.S. Food and Drug Administration (FDA) this quarter to discuss its OPC1 Investigational New Drug (IND) amendment submission, which would enable the clinical performance and safety testing of an improved delivery system to administer OPC1 in both acute and chronic spinal cord injury patients. In support of the Company’s planned regulatory interactions, most of the verification and validation activities for this novel parenchymal spinal delivery system and its preclinical testing have been completed, with additional preclinical activities also near completion.
About OPC1
OPC1 is an oligodendrocyte progenitor cell (OPC) transplant therapy designed to provide clinically meaningful improvements to motor recovery in individuals with acute spinal cord injuries (SCI). OPCs are naturally occurring precursors to the cells which provide electrical insulation for nerve axons in the form of a myelin sheath. SCI occurs when the spinal cord is subjected to a severe crush or contusion injury and typically results in severe functional impairment, including limb paralysis, aberrant pain signaling, and loss of bladder control and other body functions. There are approximately 18,000 new spinal cord injuries annually in the U.S. and there currently are no FDA-approved drugs specifically for the treatment of SCI. The OPC1 program has been partially funded by a $14.3 million grant from the California Institute for Regenerative Medicine. OPC1 has received Regenerative Medicine Advanced Therapy (RMAT) designation and Orphan Drug designation from the U.S. Food and Drug Administration (FDA).
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion-dollar opportunities and include five allogeneic ("off-the-shelf") product candidates: (i) OpRegen, a retinal pigment epithelial cell therapy in development for the treatment of geographic atrophy secondary to age-related macular degeneration, is being developed under a worldwide collaboration with Roche and Genentech, a member of the Roche Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; (iii) VAC2, a dendritic cell therapy produced from Lineage’s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer; (iv) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; and (v) PNC1, a photoreceptor neural cell therapy for the treatment of vision loss due to photoreceptor dysfunction or damage. For more information, please visit https://www.lineagecell.com or follow the company on Twitter @LineageCell.
Forward-Looking Statements
Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as "believe," "aim," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "can," "plan," "potential," "predict," "seek," "should," "would," "contemplate," "project," "target," "tend to," or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to the issuance of patents within the coming months and their terms for expiration; the potential value and benefits of these patents; any potential competitive advantages of our cell production capabilities; our ability to reduce or eliminate third-party payments through the development of new intellectual property; our collaboration and license agreement with Roche and Genentech and the timing of anticipated FDA interactions, preclinical activities, clinical trials, and clinical data updates related to our programs. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, but not limited to, the following risks: that patents we expect to be issued may not be issued as soon as expected or at all, or if issued, may expire earlier than expected; that potential benefits of newly developed intellectual property to the Company may not be realized as quickly as expected or at all; that we may need to allocate our cash to unexpected events and expenses causing us to use our cash more quickly than expected; that positive findings in early clinical and/or nonclinical studies of a product candidate may not be predictive of success in subsequent clinical and/or nonclinical studies of that candidate; that competing alternative therapies may adversely impact the commercial potential of OpRegen; that Roche and Genentech may not successfully advance OpRegen or be successful in completing further clinical trials for OpRegen and/or obtaining regulatory approval for OpRegen in any particular jurisdiction; that we may not establish new partnerships or expand existing collaborations; that Lineage may not be able to manufacture sufficient clinical quantities of its product candidates in accordance with current good manufacturing practice; and those risks and uncertainties inherent in Lineage’s business and other risks discussed in Lineage’s filings with the Securities and Exchange Commission (SEC). Lineage’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading "Risk Factors" in Lineage’s periodic reports with the SEC, including Lineage’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the SEC and its other reports, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221010005173/en/
Contacts
Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
(mailto://ir@lineagecell.com)
(442) 287-8963
LifeSci Advisors
Daniel Ferry
(mailto://daniel@lifesciadvisors.com)
(617) 430-7576
Russo Partners – Media Relations
Nic Johnson or David Schull
(mailto://Nic.johnson@russopartnersllc.com)
(mailto://David.schull@russopartnersllc.com)
(212) 845-4242
NEWS -- CytoSorbents Announces Pending Retirement of Chief Financial Officer Kathleen P. Bloch
PRINCETON, N.J., Oct. 7, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced today that its Chief Financial Officer, Kathleen P. Bloch, MBA, CPA, plans to retire on March 31, 2023 at age 68, following a distinguished decade-long career at the Company. A search has been initiated for Ms. Bloch's replacement. Meanwhile, following her retirement next year, Ms. Bloch will continue as a consultant of the Company to provide, among other services, continuity during the transition of her successor.
Ms. Bloch stated, "It has been a privilege and a pleasure to be a part of the incredible team at CytoSorbents over the past 9 plus years, during which time we have achieved rapid growth in both our company and our business, while helping to save the lives of patients around the world. It has been an exciting and personally fulfilling journey, made more enjoyable by the positive chemistry and culture of our management team and employee base, which is a major reason why I have postponed my retirement for so long. But I am pleased to have been a major contributor, and look back on the accomplishments of my talented and highly capable finance and accounting teams in both the U.S. and Europe with pride. I believe the Company has an exciting future ahead, and look forward to an anticipated return to sales growth and the achievement of our first U.S. FDA marketing approval. Although I will retire formally at the end of March next year, I intend to continue supporting the Company from the sidelines as both a long-term shareholder and as a consultant as needed."
Dr. Phillip Chan, Chief Executive Officer of CytoSorbents stated, "Kathy is an outstanding CFO and member of our leadership team, and we are extremely fortunate to have her. Among Kathy's many accomplishments, she was instrumental in our successful up-listing to Nasdaq. As CFO of a public company, Kathy has also been responsible for timely and consistent accounting, SEC reporting, and Sarbanes Oxley compliance, and has worked diligently to design and strengthen our system of internal controls. Kathy was also key in the capitalization of our company by supporting numerous successful fund raisings in cumulative excess of $140 million and establishing a favorable debt facility, enabling us to finance the global expansion of our business to 75 countries and to build a state-of-the-art manufacturing facility. Through maintenance of a strong network of investors, bankers, and analysts, and presentations and investor meetings at numerous conferences, Kathy supports analyst coverage from six investment banks, and has been a welcomed partner in our investor relations outreach. Meanwhile, she has developed, mentored, and led an outstanding group of finance and accounting professionals who expertly manage a broad and complex range of international trade and accounting issues, from consolidation of subsidiary results based in different currencies, to international tax policies. Lastly, Kathy has overseen the modernization of our finance and accounting information technology systems to support our growing needs."
"We are also very proud of Kathy's well-deserved accomplishments outside of the Company. Kathy was the 2016 NJ BIZ Magazine's Public Company CFO of the Year, currently serves as Chapter President and Member of the Board of Directors of the Mercer Chapter of the New Jersey Society of Certified Public Accountants (NJCPA), and was the recipient of the 2021 NJCPA Ovation Award recognizing CPAs who have had an impact on their jobs, communities, and the accounting profession."
Dr. Chan concluded, "Above all, Kathy has been a tremendous pleasure to work with as a trusted colleague who embodies the values of our Company as a positive, kind, committed, and generous leader who puts our people and our mission ahead of herself. We feel honored to cap her outstanding financial executive career in successful private and public companies, and will miss her greatly. On behalf of the entire Company and our Board of Directors, we thank Kathy for her many years of dedication and service to the Company and wish her all the best in retirement and in this next phase in her life."
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and in cardiac surgery through blood purification. Its lead product, CytoSorb®, is approved in the European Union and distributed in 75 countries worldwide. It is an extracorporeal cytokine adsorber that reduces "cytokine storm" or "cytokine release syndrome" in common critical illnesses that can lead to massive inflammation, organ failure and patient death. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments. CytoSorb is also used during and after cardiothoracic surgery to remove inflammatory mediators that can lead to postoperative complications, including multiple organ failure. As of June 30, 2022, more than 179,000 CytoSorb devices have been used cumulatively. CytoSorb was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor and rivaroxaban removal in cardiothoracic surgery procedures. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure. The DrugSorb™-ATR antithrombotic removal system, based on the same polymer technology as CytoSorb, also received two FDA Breakthrough Device Designations, one for the removal of ticagrelor and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic procedures. The company has initiated two FDA-approved pivotal studies to support FDA marketing approval of DrugSorb-ATR in the United States. The first is the randomized, controlled STAR-T (Safe and Timely Antithrombotic Removal-Ticagrelor) study of 120 patients at 30 centers to evaluate whether intraoperative use of DrugSorb-ATR can reduce the perioperative risk of bleeding in patients receiving ticagrelor and undergoing cardiothoracic surgery. The second study is the STAR–D (Safe and Timely Antithrombotic Removal-Direct Oral Anticoagulants) randomized, controlled trial of 120 patients at 30 centers evaluating the intraoperative use of DrugSorb-ATR to reduce perioperative bleeding risk in patients undergoing cardiothoracic surgery and taking direct oral anticoagulants, including apixaban and rivaroxaban.
CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of approximately $48 million from DARPA, the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S. Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM), Air Force Material Command (USAF/AFMC), and others. The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, DrugSorb™-ATR, ContrastSorb, and others. For more information, please visit the Company's websites at https://www.cytosorbents.com and https://www.cytosorb.com or follow us on Facebook and Twitter.
Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, expectations regarding the future impacts of COVID-19 or the ongoing conflict between Russia and the Ukraine, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 10, 2022, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
CytoSorbents Contact:
Kathleen Bloch
(732) 398-5429
mailto://kbloch@cytosorbents.com
U.S. Public Relations Contact:
Eric Kim
Rubenstein Public Relations
212-805-3052
mailto://ekim@rubensteinpr.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/cytosorbents-announces-pending-retirement-of-chief-financial-officer-kathleen-p-bloch-301643417.html
SOURCE CytoSorbents Corporation
NEWS -- Plus Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on October 20, 2022
October 06 2022 - 07:00AM
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report third quarter 2022 financial results on Thursday, October 20, 2022, after market close. Plus Therapeutics’ management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update.
A live webcast will be available at https://ir.plustherapeutics.com/events.
Participants may also pre-register any time before the call here. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.
Following the live call, a replay will be available on the Company’s website under the 'For Investor' section. The webcast will be available on the Company’s website for 90 days following the live call.
About Plus Therapeutics, Inc.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the development, manufacture, and commercialization of complex and innovative treatments for patients battling cancer and other life-threatening diseases. Our proprietary nanotechnology platform is currently centered around the enhanced delivery of a variety of drugs using novel liposomal encapsulation technology. Liposomal encapsulation has been extensively explored and undergone significant technical and commercial advances since it was first developed. Our platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at https://PlusTherapeutics.com and https://ReSPECT-Trials.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “designed to,” “will,” “can,” “potential,” “focus,” “preparing,” “next steps,” “possibly,” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of 186RNL including the ability of 186RNL to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company’s future performance including the next steps in developing the Company’s current assets; the Company’s clinical trials including statements regarding the timing and characteristics of the ReSPECT-LM trial; possible negative effects of 186RNL; the continued evaluation of 186RNL for LM including through evaluations via a second patient cohort; capital requirements, timing and speed of development; and the intended functions of the Company’s platform and expected benefits from such functions.
The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the Company’s actual results may differ, including materially, from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, the following: the early stage of the Company’s product candidates and therapies, the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash, the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the regenerative medicine field, among others; changes in the CPRIT program; and additional risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor Contact
Peter Vozzo
ICR Westwicke
(443) 377-4767
mailto://Peter.Vozzo@westwicke.com
Media Contact
Terri Clevenger
ICR Westwicke
(203) 856-4326
mailto://Terri.Clevenger@westwicke.com
NEWS -- Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting
DUBLIN, Ohio, October 05, 2022--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that results from the Company’s ongoing preclinical studies evaluating targeted immunotherapy for cancer based on the Manocept platform have been accepted for presentation at the 37th Annual Meeting of the Society for Immunotherapy of Cancer ("SITC") to be held at the Boston Convention & Exhibition Center in person and virtually November 8-12, 2022 in Boston, MA.
The abstract, "Synthetic CD206 Targeted Constructs Carrying Paclitaxel or Novel Bisphosphonate Payloads Alter Macrophages Towards Pro-inflammatory Phenotypes; The Paclitaxel Construct Improves the Efficacy of anti-CTLA4 in CT26 Tumors" (Abstract #1161), will be presented as a poster on November 10, 9 am to 9 pm in the conference center’s poster hall. Further details of the abstract will be announced in a future press release once the meeting embargo is lifted.
Abstract title and session information can be found on the SITC Annual Meeting website at: https://www.sitcancer.org/2022/home.
Dr. Michael Rosol, Chief Medical Officer for Navidea, said, "We are delighted by the opportunity to present these important preclinical results at this internationally recognized meeting." Dr. Rosol continued, "We continue to develop the Manocept platform, using its potent ability to target macrophages, for the development of new immunotherapies for diseases including cancer."
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts. For more information, please visit https://www.navidea.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements include our expectations regarding pending litigation and other matters. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: our history of operating losses and uncertainty of future profitability; the final outcome of any pending litigation; our ability to successfully complete research and further development of our drug candidates; the timing, cost and uncertainty of obtaining regulatory approvals of our drug candidates; our ability to successfully commercialize our drug candidates; dependence on royalties and grant revenue; our ability to implement our growth strategy; anticipated trends in our business; our limited product line and distribution channels; advances in technologies and development of new competitive products; our ability to comply with the NYSE American continued listing standards; our ability to maintain effective internal control over financial reporting; the impact of the current coronavirus pandemic; and other risk factors detailed in our most recent Annual Report on Form 10-K and other SEC filings. You are urged to carefully review and consider the disclosures found in our SEC filings, which are available at http://www.sec.gov or at http://ir.navidea.com.
Investors are urged to consider statements that include the words "will," "may," "could," "should," "plan," "continue," "designed," "goal," "forecast," "future," "believe," "intend," "expect," "anticipate," "estimate," "project," and similar expressions, as well as the negatives of those words or other comparable words, to be uncertain forward-looking statements.
You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be incorrect. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this report. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221005005778/en/
Contacts
Investor Relations Contact
Navidea Biopharmaceuticals, Inc.
Jeffrey Smith
Vice President of Operations
614-822-2365
mailto://jsmith@navidea.com
Nano Mobile @OfficialVnth · 20h
Replying to
@ChaseMacTrades
A bunch of calls this week. Should have some stuff to share very soon $VNTH
NEWS -- Oncolytics Biotech® Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting
Interim results from the phase 1/2 GOBLET study's pancreatic cancer cohort to be presented in a poster on November 11th and discussed during a key opinion leader webinar on November 14th at 10 a.m. ET
SAN DIEGO, and CALGARY, AB, Oct. 5, 2022 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the acceptance of two abstracts for poster presentations at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, which is taking place both virtually and in-person at the Boston Convention and Exhibition Center in Boston, MA, from November 8 – 12, 2022.
Both abstracts will be published by SITC at 8:00 a.m. ET on November 7, 2022. Additional details on the abstracts and corresponding poster presentations are shown below.
Title: Pelareorep combined with atezolizumab and chemotherapy demonstrates encouraging results as first-line treatment in advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients – Interim results from the GOBLET study
Abstract Number: 650
Poster Session Date and Time: November 11, 2022 from 9:00 a.m. – 8:30 p.m. ET
Poster Session Location: Boston Convention and Exhibition Center, Hall C
Title: The oncolytic virus pelareorep in combination with immune checkpoint inhibitor activates T-cell functioning in early breast cancer patients – immunophenotype results from AWARE-1 study
Abstract Number: 548
Poster Session Date and Time: November 11, 2022 from 9:00 a.m. – 8:30 p.m. ET
Poster Session Location: Boston Convention and Exhibition Center, Hall C
Key Opinion Leader Webinar on Pancreatic Cancer and Interim Phase 1/2 GOBLET Study Data
Oncolytics will host a key opinion leader (KOL) webinar to discuss the current treatment landscape and unmet medical need in pancreatic cancer, as well as the interim GOBLET study results that will be presented at the SITC conference on November 14, 2022 at 10 a.m. ET. The webinar will include both formal presentations and a live question and answer session.
To register for the webinar, please click here.
About GOBLET
The GOBLET (Gastrointestinal tumOrs exploring the treatment comBinations with the oncolytic reovirus peLarEorep and anTi-PD-L1) study is a phase 1/2 multiple indication study in advanced or metastatic gastrointestinal tumors. The study is being conducted at 14 centers in Germany. The co-primary endpoints of the study are objective response rate (ORR) assessed at week 16 and safety. Key secondary and exploratory endpoints include additional efficacy assessments and evaluation of potential biomarkers (T cell clonality and CEACAM6). The study employs a Simon two-stage design with Stage 1 comprising four treatment groups expected to enroll a total of approximately 55 patients:
NEWS -- Plus Therapeutics Announces Patient Webinar in Recognition of Breast Cancer Awareness Month
Principal Investigator Dr. Andrew Brenner to Lead Musella Foundation Live Webinar
AUSTIN, Texas, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that Dr. Andrew Brenner, M.D., Ph.D., Professor of Medicine, Neurology, and Neurosurgery at The University of Texas Health Science Center at San Antonio and principal investigator of the ReSPECT-LM clinical trial, is scheduled to conduct a live patient-focused webinar entitled, "A Promising New Targeted Radiation Therapy for Leptomeningeal Metastases in Breast Cancer, Lung Cancer, and Other Malignancies: An Introduction" on Sunday, October 9, 2022 at 7:00 PM Eastern.
Leptomeningeal metastases is a cancer in the cerebrospinal fluid and in the membranes surrounding the brain and spinal cord, occurring as a result of an advanced cancer spreading. It is most common in breast cancer, but does occur in lung cancer and other cancers.
The event, part of the Musella Foundation Webinar Series, is to be presented live on the Foundation’s website at virtualtrials.com/webinar/ through a Zoom room. Participants are asked to join the digital room 5 minutes before the event and may ask questions live or email questions in advance to mailto://musella@virtualtrials.com.
About Andrew Brenner, M.D. Ph.D.
Dr. Brenner holds the Kolitz/Zachry Endowed Chair Neuro-Oncology Research and is the Co-Leader, Experimental and Developmental Therapeutics Program at UT Health Science Center San Antonio (UTHSCSA) as well as a practicing oncologist at Texas Oncology in Austin. His experience with first-in-human studies includes involvement with the development of approximately 30 compounds as either a co-Investigator or Principal Investigator since 2008. This also includes first-in-class experience (gene therapy, liposomal encapsulated microRNA mimic, liposomal encapsulated therapeutics, metabolic inhibitors, etc.). In this role he has been responsible for authoring protocols, IND and SPA discussions with the FDA, oversight of multi-center studies (including FDA funded studies), solicitation of bids by CROs, data analysis (primarily PD and some PK), and presentation of results. He is familiar with all phases of study conduct.
Dr. Brenner is a graduate of Texas A&M University where he earned his bachelor’s degree in biochemistry and went on to earn his doctorate in biological science and tumor biology at The University of Texas M.D. Anderson Cancer Center Science Park. Dr. Brenner received his medical degree from the Texas Tech University Health Sciences Center and completed a residency in internal medicine at Scott and White Hospital in Lubbock. He completed his fellowship in hematology and medical oncology at the UT Health Science Center.
About The Musella Foundation For Brain Tumor Research & Information
The Musella Foundation is a 501(c)(3) nonprofit public charity dedicated to helping brain tumor patients through emotional and financial support, education, advocacy and raising money for brain tumor research. Based in Hewlett, N.Y., the foundation was founded by Dr. Al Musella, DPM, a podiatrist in private practice in Hewlett. The foundation has awarded over $4.7 million in direct patient assistance to help patients receive treatment. More information may be found at https://www.virtualtrials.com.
About Plus Therapeutics
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the development, manufacture, and commercialization of complex and innovative treatments for patients battling cancer and other life-threatening diseases. Our proprietary nanotechnology platform is currently centered around the enhanced delivery of a variety of drugs using novel liposomal encapsulation technology. Liposomal encapsulation has been extensively explored and undergone significant technical and commercial advances since it was first developed. Our platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at https://PlusTherapeutics.com and https://ReSPECT-Trials.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “designed to,” “will,” “can,” “potential,” “focus,” “preparing,” “next steps,” “possibly,” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of 186RNL including the potential ability of 186RNL to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company’s future performance including the next steps in developing the Company’s current assets; the Company’s clinical trials including statements regarding the timing and characteristics of the ReSPECT-LM trial; possible negative effects of 186RNL; the continued evaluation of 186RNL for LM including through evaluations via a second patient cohort; capital requirements, timing and speed of development; cash needs and anticipated forecast; and the intended functions of the Company’s platform and expected benefits from such functions.
The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: requirements to comply with the terms of the CPRIT grant; the early stage of the Company’s product candidates and therapies, and the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash; the outcome of the Company’s partnering/licensing efforts; risks associated with laws or regulatory requirements applicable to the Company, market conditions, product performance, litigation or potential litigation, and competition within the regenerative medicine field, among others; changes in the CPRIT program; changing sources and uses of cash; and additional risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may also be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor Contact
Peter Vozzo
ICR Westwicke
(443) 377-4767
mailto://Peter.Vozzo@westwicke.com
Media Contact
Terri Clevenger
ICR Westwicke
(203) 856-4326
mailto://Terri.Clevenger@westwicke.com
NEWS -- Lineage to Present at Alliance for Regenerative Medicine 2022 Cell & Gene Meeting on the Mesa
CARLSBAD, Calif., October 04, 2022--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that Brian M. Culley, Lineage’s Chief Executive Officer, will present at the Alliance for Regenerative Medicine 2022 Cell & Gene Meeting on the Mesa, on October 12th, 2022 at 2:15pm PT / 5:15pm ET at the Park Hyatt Aviara, Carlsbad, CA. Virtual meeting attendance is available and includes a livestream of Lineage’s presentation and the ability to view all conference sessions on-demand. Interested parties can visit the 2022 Cell & Gene Meeting on the Mesa website for full information on the conference, including registration.
The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Tackling the commercialization hurdles facing the cell and gene therapy sector today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies. The program features expert-led panels, extensive partnering capabilities, exclusive networking opportunities, and dedicated presentations by the leading publicly traded and privately held companies in the space. This conference enables key partnerships through more than 3,000 one-on-one meetings while highlighting the significant clinical and commercial progress in the field.
About the Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies. ARM promotes legislative, regulatory, reimbursement and manufacturing initiatives to advance this innovative and transformative sector, which includes cell therapies, gene therapies and tissue-engineered therapies. In its 13-year history, ARM has become the global voice of the sector, representing the interests of 450+ members worldwide, including small and large companies, academic research institutions, major medical centers and patient groups.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include five allogeneic ("off-the-shelf") product candidates: (i) OpRegen, a retinal pigment epithelial cell therapy in development for the treatment of geographic atrophy secondary to age-related macular degeneration, is being developed under a worldwide collaboration with Roche and Genentech, a member of the Roche Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; (iii) VAC2, a dendritic cell therapy produced from Lineage’s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer; (iv) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; and (v) PNC1, a photoreceptor neural cell therapy for the treatment of vision loss due to photoreceptor dysfunction or damage. For more information, please visit https://www.lineagecell.com or follow the company on Twitter @LineageCell.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221004005157/en/
Contacts
Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
(mailto://ir@lineagecell.com)
(442) 287-8963
LifeSci Advisors
Daniel Ferry
(mailto://daniel@lifesciadvisors.com)
(617) 430-7576
Russo Partners – Media Relations
Nic Johnson or David Schull
(mailto://Nic.johnson@russopartnersllc.com)
(mailto://David.schull@russopartnersllc.com)
(212) 845-4242
NEWS -- Plus Therapeutics to Share Data in Oral Presentations from Ongoing ReSPECT™ Clinical Trials at the 35th Annual Congress of the European Association of Nuclear Medicine
Leptomeningeal metastases data has been selected as a “Top Rated Oral Presentation” by EANM
AUSTIN, Texas, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it will present data from two ongoing clinical trials evaluating the Company’s lead investigational targeted radiotherapeutic, Rhenium-186 NanoLiposome (186RNL), in recurrent glioblastoma and leptomeningeal metastases at the 35th Annual Congress of the European Association of Nuclear Medicine (EANM), being held October 15-19, 2022 in Barcelona, Spain.
Abstracts are currently available online in the latest edition of the European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI) Supplement by Springer, here. For more information on the EANM Annual Congress visit, https://eanm22.eanm.org/.
A copy of the presentations will also be available under the Presentations tab of the Investors section of the Company’s website at the time of the presentations at https://ir.plustherapeutics.com.
About Plus Therapeutics
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the development, manufacture, and commercialization of complex and innovative treatments for patients battling cancer and other life-threatening diseases. Our proprietary nanotechnology platform is currently centered around the enhanced delivery of a variety of drugs using novel liposomal encapsulation technology. Liposomal encapsulation has been extensively explored and undergone significant technical and commercial advances since it was first developed. Our platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at https://PlusTherapeutics.com and https://ReSPECT-Trials.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “designed to,” “will,” “can,” “potential,” “focus,” “preparing,” “next steps,” “possibly,” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of 186RNL including the ability of 186RNL to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company’s future performance including the next steps in developing the Company’s current assets; the Company’s clinical trials including statements regarding the timing and characteristics of the ReSPECT-GBM and ReSPECT-LM clinical trials; possible negative effects of 186RNL; the continued evaluation of 186RNL including through evaluations in additional patient cohorts; and the intended functions of the Company’s platform and expected benefits from such functions.
The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the Company’s actual results may differ, including materially, from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, the following: the early stage of the Company’s product candidates and therapies, the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash, the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field, among others; and additional risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor Contact
Peter Vozzo
ICR Westwicke
(443) 377-4767
mailto://Peter.Vozzo@westwicke.com
Media Contact
Terri Clevenger
ICR Westwicke
(203) 856-4326
mailto://Terri.Clevenger@westwicke.com
NEWS -- Lineage Establishes New R&D Facility in U.S. and Expands Current GMP Manufacturing Facility in Israel
Expansions Expected to Support Process Development and Production of Current and Future Cell Transplant Programs
CARLSBAD, Calif., October 03, 2022--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today the opening of a new research and development (R&D) facility in Carlsbad, California, and the expansion of its Good Manufacturing Practice (GMP) manufacturing facility based in Jerusalem, Israel. Lineage’s new Carlsbad facility will broaden the Company’s R&D capabilities in the U.S. and support the development of current and future allogeneic cell transplant programs. The expansion of Lineage’s Israel-based facility will increase the Company’s infrastructure, including development and optimization of larger-scale clinical manufacturing processes, and continued execution under its ongoing collaboration with Roche and Genentech for RG6501 (OpRegen®), a retinal pigment epithelium cell replacement therapy which has completed enrollment in a Phase 1/2a clinical trial for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
"We have elected to increase our R&D footprint at our existing GMP manufacturing facility and establish a new R&D facility in Carlsbad, California," stated Brian M. Culley, Lineage CEO. "These steps will permit us to expand our process development and analytical testing capabilities and conduct exploratory work on future programs, whether owned by us or our current or future partners. This move also is expected to reduce our reliance on certain vendors, which may reduce costs and risks of timeline uncertainty or supply chain disruption. The additional capacity also can help us become an even more capable partner in prospective alliances for new products and allow us to explore additional uses for our current cell transplant programs."
Mr. Culley added, "Challenges in the biotech sector are unlikely to persist indefinitely. We believe it is important to take steps, even in this environment, to be positioned for a future recovery. The modest investments we are making today, partially offset by the termination of the lease for our research facility in Alameda, California in January of next year, will help centralize our operations and put us in a position of greater readiness for future success."
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include five allogeneic ("off-the-shelf") product candidates: (i) OpRegen, a retinal pigment epithelial cell therapy in development for the treatment of geographic atrophy secondary to age-related macular degeneration, is being developed under a worldwide collaboration with Roche and Genentech, a member of the Roche Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; (iii) VAC2, a dendritic cell therapy produced from Lineage’s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer; (iv) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; and (v) PNC1, a photoreceptor neural cell therapy for the treatment of vision loss due to photoreceptor dysfunction or damage. For more information, please visit https://www.lineagecell.com or follow the company on Twitter @LineageCell.
Forward-Looking Statements
Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as "believe," "aim," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "can," "plan," "potential," "predict," "seek," "should," "would," "contemplate," "project," "target," "tend to," or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to: the potential benefits of the new and expanded facilities to the Company and its operations, including the broadening of the Company’s R&D capabilities, increasing development and optimization of larger-scale clinical manufacturing processes, the expansion of the Company’s process development and analytical testing capabilities and ability to conduct exploratory work on future programs, the increase in the Company’s manufacturing facilities, the decreased reliance on certain vendors, the reduction in costs and risks of timeline uncertainty and supply chain disruption, and the improvement in the Company’s position of greater readiness for future success. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, but not limited to, the following risks: that potential benefits of the new and expanded facilities to the Company and its operations may not be realized as quickly as expected or at all; that we may need to allocate our cash to unexpected events and expenses causing us to use our cash more quickly than expected; that positive findings in early clinical and/or nonclinical studies of a product candidate may not be predictive of success in subsequent clinical and/or nonclinical studies of that candidate; that competing alternative therapies may adversely impact the commercial potential of OpRegen; that Roche and Genentech may not successfully advance OpRegen or be successful in completing further clinical trials for OpRegen and/or obtaining regulatory approval for OpRegen in any particular jurisdiction; that we may not establish new partnerships or expand existing collaborations; that we do not successfully broaden awareness of our mission or accomplishments; that Lineage may not be able to manufacture sufficient clinical quantities of its product candidates in accordance with current good manufacturing practice; and those risks and uncertainties inherent in Lineage’s business and other risks discussed in Lineage’s filings with the Securities and Exchange Commission (SEC). Lineage’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading "Risk Factors" in Lineage’s periodic reports with the SEC, including Lineage’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the SEC and its other reports, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221003005286/en/
Contacts
Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
(mailto://ir@lineagecell.com)
(442) 287-8963
LifeSci Advisors
Daniel Ferry
(mailto://daniel@lifesciadvisors.com)
(617) 430-7576
Russo Partners – Media Relations
Nic Johnson or David Schull
(mailto://Nic.johnson@russopartnersllc.com)
(mailto://David.schull@russopartnersllc.com)
(212) 845-4242
NEWS -- Tokens.com to Speak at the W3BX Investor Summit
TORONTO, October 03, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or the "Company"), a publicly-traded company that invests in web3 assets and builds businesses linked to crypto staking, the metaverse and play-to-earn gaming, is pleased to share that the company will be attending this year’s W3BX Investor Summit and Expo, which will be taking place at the Wynn Las Vegas from October 10th to 13th. Tokens.com’s CEO, Andrew Kiguel, will deliver a keynote address at the event. He will be speaking alongside other visionary CEOs, prominent futurists and industry experts from Mastercard, O’leary Ventures, Amazon Web Services, and Kraken.
This year’s W3BX Investor Summit will host a collection of keynotes, panels, and fireside chats focusing on investing in web3. The conference takes place over four days and will be hosting guests ranging from Fortune 500 companies to venture capitalists, retail and institutional investors, hedge funds, family offices, and Blue-Chip NFT Collectors. The event will feature senior executives from over 100 private and public companies all within the growing web3 sector.
Senior management from Tokens.com, and its subsidiaries Metaverse Group and Hulk Labs will be in attendance and will be participating in a panel discussion. In addition, Tokens.com will have a booth on the Expo floor where attendees will have the opportunity to learn more about the Company directly from its leaders. Those interested in learning more are encouraged to connect with the team at the Tokens.com expo booth number 218 or reach out via email to mailto://Contact@tokens.com.
"As a keynote at this year’s W3BX Investor Summit and Expo, I’ll be connecting with new and prospective Tokens.com shareholders," said Andrew Kiguel, Tokens.com CEO. "This is a best-in-class event and we are looking forward to educating a new audience on the breadth of web3 businesses that we give investors exposure to through Tokens.com and our subsidiaries, Hulk Labs and Metaverse Group."
For more information on the W3BX investor summit and expo please visit https://web3expo.live/.
About Tokens.com
Tokens.com Corp is a publicly traded company that invests in Web3 assets and builds Web3 businesses. The Company focuses on three operating segments: i) crypto staking, ii) the metaverse and, iii) play-to-earn crypto gaming. Tokens.com owns digital assets and operating businesses within each of these three segments.
Staking operations occur within Tokens.com. Metaverse operations occur within a subsidiary called Metaverse Group. Crypto gaming operations occur within a subsidiary called Hulk Labs. All three businesses are tied together by the utilization of blockchain technology and are linked to high-growth macro trends within Web3. Through sharing resources and infrastructure across these business segments, Tokens.com is able to efficiently incubate these businesses from inception to revenue generation.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities on Twitter, LinkedIn, and YouTube.
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at https://www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221003005081/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media Contact: Ali Clarke – Talk Shop Media
Email: mailto://ali@talkshopmedia.com
NEWS -- Tokens.com to Speak at the W3BX Investor Summit
TORONTO, October 03, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or the "Company"), a publicly-traded company that invests in web3 assets and builds businesses linked to crypto staking, the metaverse and play-to-earn gaming, is pleased to share that the company will be attending this year’s W3BX Investor Summit and Expo, which will be taking place at the Wynn Las Vegas from October 10th to 13th. Tokens.com’s CEO, Andrew Kiguel, will deliver a keynote address at the event. He will be speaking alongside other visionary CEOs, prominent futurists and industry experts from Mastercard, O’leary Ventures, Amazon Web Services, and Kraken.
This year’s W3BX Investor Summit will host a collection of keynotes, panels, and fireside chats focusing on investing in web3. The conference takes place over four days and will be hosting guests ranging from Fortune 500 companies to venture capitalists, retail and institutional investors, hedge funds, family offices, and Blue-Chip NFT Collectors. The event will feature senior executives from over 100 private and public companies all within the growing web3 sector.
Senior management from Tokens.com, and its subsidiaries Metaverse Group and Hulk Labs will be in attendance and will be participating in a panel discussion. In addition, Tokens.com will have a booth on the Expo floor where attendees will have the opportunity to learn more about the Company directly from its leaders. Those interested in learning more are encouraged to connect with the team at the Tokens.com expo booth number 218 or reach out via email to mailto://Contact@tokens.com.
"As a keynote at this year’s W3BX Investor Summit and Expo, I’ll be connecting with new and prospective Tokens.com shareholders," said Andrew Kiguel, Tokens.com CEO. "This is a best-in-class event and we are looking forward to educating a new audience on the breadth of web3 businesses that we give investors exposure to through Tokens.com and our subsidiaries, Hulk Labs and Metaverse Group."
For more information on the W3BX investor summit and expo please visit https://web3expo.live/.
About Tokens.com
Tokens.com Corp is a publicly traded company that invests in Web3 assets and builds Web3 businesses. The Company focuses on three operating segments: i) crypto staking, ii) the metaverse and, iii) play-to-earn crypto gaming. Tokens.com owns digital assets and operating businesses within each of these three segments.
Staking operations occur within Tokens.com. Metaverse operations occur within a subsidiary called Metaverse Group. Crypto gaming operations occur within a subsidiary called Hulk Labs. All three businesses are tied together by the utilization of blockchain technology and are linked to high-growth macro trends within Web3. Through sharing resources and infrastructure across these business segments, Tokens.com is able to efficiently incubate these businesses from inception to revenue generation.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities on Twitter, LinkedIn, and YouTube.
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at https://www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221003005081/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media Contact: Ali Clarke – Talk Shop Media
Email: mailto://ali@talkshopmedia.com
Here is the latest tweet:
Nano Mobile @OfficialVnth · 7m
We have decided on a new name for $vnth which will be released once filed with the state of Nevada. Now that a name has been chosen, we’ll begin rolling out our new company website and social media links. Talks are ongoing with #EV charge installation companies to partner with.
NEWS -- Navidea Biopharmaceuticals Appoints Joshua Wilson to the Board of Directors; Announces Dates Related to its 2022 Annual Meeting of Stockholders
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the appointment of Joshua (“Josh”) Wilson to its Board of Directors, effective September 30, 2022, with a term ending concurrently with the Company’s 2024 annual stockholders’ meeting.
Mr. Wilson is a seasoned banking and finance executive with more than 23 years of financial services and family office experience. During his career, Mr. Wilson focused his efforts on raising capital and streamlining company operations for profit and non-profit entities, raising more than $500 million. Currently, Mr. Wilson is the Chief Executive Officer for the UpSwing Foundation, focusing on raising capital for the vertical construction of UpSwing Foundation’s World Headquarters and overseeing all day-to-day operations of its business in support of the Foundation’s mission of “Connecting People and Catapulting Dreams-Together,” achieved through access to elite athletic facilities, multi-sport training, and scholarship opportunities. Mr. Wilson is also the Executive Director of G2G Ventures, a Colorado-based single-family office, focusing on the creation of its first four private equity partnership funds with assets in energy, industrial warehousing, biotechnology and biopharmaceuticals. Mr. Wilson has served in both of these positions since June 2022. From 2017 to June 2022, Mr. Wilson was State President-CO/WY-AZ-CA of First Western Trust Bank, and from 2011 to 2016, he served as Chief Financial Officer/Family Office Executive of Central Resources, Inc. Prior to that, Mr. Wilson held roles of increasing responsibility at multiple financial institutions, including Market President-Denver of First Western Trust Bank, Senior Vice President of Vectra Private Bank, and Vice President of Bank One/JP Morgan Chase. Mr. Wilson currently serves on the board of directors of Lynx Energy ULC, with prior board experience with First Western Trust. Mr. Wilson currently serves on the Audit and Finance Committees of National Western Stock Show and The Club at Rolling Hills. Mr. Wilson received his B.S. in Business Administration from Regis University.
Dr. Michael Rosol, Chief Medical Officer for Navidea, said, “Navidea is pleased to add Josh, a highly respected and exceptionally talented individual, to its Board of Directors. His experience will help guide the Company through its next phases of growth and development.”
Navidea Board Chair Alexander L. Cappello said, “I am proud to welcome Josh to the Navidea Board of Directors. His management experience as an executive officer, success in capital raises and finance, demonstrated leadership, and board experience combine to make him an excellent addition to Navidea.”
Navidea also announced that its 2022 Annual Meeting of Stockholders (“2022 Annual Meeting”) will be held on Thursday, December 8, 2022 at 1:00 pm Eastern Standard Time. The 2022 Annual Meeting will be a completely virtual meeting conducted via webcast. The Board of Directors has fixed the close of business on October 10, 2022 as the record date for the determination of stockholders entitled to notice of and to vote during the 2022 Annual Meeting and any adjournment thereof.
Because the date of the 2022 Annual Meeting is more than 30 days after the anniversary of the 2021 Annual Meeting of Stockholders, the Company is providing notice of the due date for the submission of any qualified stockholder proposals or qualified stockholder director nominations with respect to the 2022 Annual Meeting.
In accordance with Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), any stockholder proposal intended to be considered for inclusion in the Company’s proxy materials for the 2022 Annual Meeting must be delivered to, or mailed to and received at, the Company’s executive offices located at 4995 Bradenton Avenue, Suite 240, Dublin, Ohio 43017, Attention: Corporate Secretary, on or before the close of business on October 10, 2022, which the Company has determined to be a reasonable time before it expects to begin to print and distribute its proxy materials for the 2022 Annual Meeting. In addition to complying with this deadline, stockholder proposals intended to be considered for inclusion in the Company’s proxy materials for the 2022 Annual Meeting must also comply with all applicable SEC rules, including Rule 14a-8 of the Exchange Act.
Pursuant to the Company’s Bylaws, any stockholder seeking to raise a proposal outside the processes of Exchange Act Rule 14a-8 or make a director nomination for consideration at the 2022 Annual Meeting must comply with the requirements of the Bylaws, including delivering such proposals and/or nominations to the executive offices of the Company located at 4995 Bradenton Avenue, Suite 240, Dublin, Ohio 43017, Attention: Corporate Secretary, by no later than close of business on October 10, 2022. Any proposal or nomination received outside of such dates will be considered untimely and will not be considered at the 2022 Annual Meeting. Any stockholder proposal or director nomination must also comply with the rules and regulations promulgated by the SEC and the Bylaws, as applicable.
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts. For more information, please visit https://www.navidea.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements include our expectations regarding pending litigation and other matters. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: our history of operating losses and uncertainty of future profitability; the final outcome of any pending litigation; our ability to successfully complete research and further development of our drug candidates; the timing, cost and uncertainty of obtaining regulatory approvals of our drug candidates; our ability to successfully commercialize our drug candidates; dependence on royalties and grant revenue; our ability to implement our growth strategy; anticipated trends in our business; our limited product line and distribution channels; advances in technologies and development of new competitive products; our ability to comply with the NYSE American continued listing standards; our ability to maintain effective internal control over financial reporting; the impact of the current coronavirus pandemic; and other risk factors detailed in our most recent Annual Report on Form 10-K and other SEC filings. You are urged to carefully review and consider the disclosures found in our SEC filings, which are available at http://www.sec.gov or at http://ir.navidea.com.
Investors are urged to consider statements that include the words “will,” “may,” “could,” “should,” “plan,” “continue,” “designed,” “goal,” “forecast,” “future,” “believe,” “intend,” “expect,” “anticipate,” “estimate,” “project,” and similar expressions, as well as the negatives of those words or other comparable words, to be uncertain forward-looking statements.
You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be incorrect. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this report. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220930005107/en/
Navidea Biopharmaceuticals, Inc.
Jeffrey Smith
Vice President of Operations
614-822-2365
mailto://jsmith@navidea.com
NEWS -- Provectus Biopharmaceuticals Establishes Research Collaboration with University of Texas Medical Branch at Galveston to Investigate Pharmaceutical-Grade Small Molecule Immunotherapy Rose Bengal for Wound Healing
KNOXVILLE, TN, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has initiated a new sponsored research program with Amina El Ayadi, PhD, Assistant Professor, Surgical Sciences Division and Jayson Jay, PhD, Postdoctoral Research Fellow and Jeane B. Kempner Scholar of the Burn, Trauma, and Critical Care Research Laboratory in the Department of Surgery at the University of Texas Medical Branch at Galveston (UTMB) to characterize the effects of Provectus’ proprietary pharmaceutical-grade rose bengal sodium (RBS) on full-thickness cutaneous wounds and during the subsequent phases of wound healing. RBS is the lead member of a class of small molecules called halogenated xanthenes that is entirely owned by Provectus.
Starting from the Texas City Disaster of 1947, the deadliest industrial accident in U.S. history and one of history’s largest non-nuclear explosions, UTMB clinicians and researchers in the Department of Surgery have developed treatments that improve the survival chances of patients with massive burns, reduce scar formation, and accelerate patient recovery. Many novel treatments discovered by UTMB researchers have been adopted by specialist burn centers around the world. The Department of Surgery’s Burn, Trauma, and Critical Care Research Laboratory is equipped with an array of cutting-edge equipment and technologies that support its research activities, including a dedicated cell culture suite, confocal microscope, flow cytometer, Comprehensive Lab Animal Monitoring System (CLAMS), and bioprinter for 3D cell culture.
Drs. El Ayadi and Jay plan to examine the safety of topically-applied, multi-dosed RBS over the wound healing periods of inflammation and cellular proliferation, determine the efficacy of RBS in a pre-clinical model of wound healing, and elucidate a spatiotemporal immune activation signature over wound healing time in a large animal model of burn and full-thickness cutaneous trauma.
About Provectus
Provectus Biopharmaceuticals, Inc. (Provectus or the Company) is a clinical-stage biotechnology company developing immunotherapy medicines for different disease areas based on a class of small molecules called halogenated xanthenes (HXs). The Company’s lead molecule is RBS. A second HX molecule has been synthesized.
Provectus’ drug discovery and development programs include investigational drugs and drug targets in oncology (clinical-stage), dermatology (clinical-stage), hematology, infectious diseases, ophthalmology (clinical-stage), animal health, tissue regeneration and repair, and wound healing, and use multiple routes of administration, such as intralesional (IL), topical (.top), oral (P.O.), inhaled (.inh), intranasal (IN), and intravenous (IV).
Information about the Company’s clinical trials can be found at the National Institutes of Health (NIH) registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company's website at https://www.provectusbio.com.
FORWARD-LOOKING STATEMENTS: The information in this press release may include “forward-looking statements,” within the meaning of U.S. securities legislation, relating to the business of Provectus and its affiliates, which are based on the opinions and estimates of Company management and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “project,” “predict,” “potential,” “targeting,” “intend,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook.
The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any particular revenue levels.
Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and Provectus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.
Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the Securities and Exchange Commission (SEC), including those described in Item 1A of:
#####
Contact:
Provectus Biopharmaceuticals, Inc.
Heather Raines, CPA
Chief Financial Officer
Phone: (866) 594-5999
I particularly liked the one he posted 32-minutes ago:
Just clearing up some confusion! Name and website soon, then the fun begins!